1
|
Jung HA, Park S, Lee SH, Ahn JS, Ahn MJ, Sun JM. Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study. ESMO Open 2023; 8:102068. [PMID: 38016250 PMCID: PMC10774959 DOI: 10.1016/j.esmoop.2023.102068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2023] [Revised: 09/26/2023] [Accepted: 10/21/2023] [Indexed: 11/30/2023] Open
Abstract
INTRODUCTION Dacomitinib showed superior progression-free survival (PFS) and overall survival compared to gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations in the ARCHER1050 study. However, because that study did not include patients with brain metastases, the efficacy of dacomitinib in patients with brain metastases has not been clarified. PATIENTS AND METHODS This single-arm phase II study enrolled 30 patients with treatment-naïve advanced NSCLC harboring activating EGFR mutations from January 2021 to June 2021 and started them on dacomitinib (45 mg/day). All patients had non-irradiated brain metastases with a diameter of ≥5 mm. The primary endpoint was confirmed intracranial objective response rate (iORR). RESULTS Patients had exon 19 deletions (46.7%) and L858R mutations in exon 21 (55.3%). The confirmed iORR was 96.7% (29/30), with an intracranial complete response of 63.3%. Median intracranial PFS (iPFS) was not reached, with 12- and 18-month iPFS rates of 78.6% [95% confidence interval (CI) 64.8% to 95.4%] and 70.4% (95% CI 54.9% to 90.1%), respectively. In the competing risk analysis, the 12-month cumulative incidence of intracranial progression was 16.7%. Regarding the overall efficacy for intracranial and extracranial lesions, the overall ORR was 96.7%, and the median PFS was 17.5 months (95% CI 15.2 months-not reached). Grade 3 or higher treatment-related adverse events were reported in 16.7% of patients, and 83.3% required a reduced dacomitinib dose to manage adverse events. However, none permanently discontinued dacomitinib treatment due to treatment-related adverse events. CONCLUSIONS Dacomitinib has outstanding intracranial efficacy in patients with EGFR-mutant NSCLC with brain metastases.
Collapse
Affiliation(s)
- H A Jung
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - S-H Lee
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J S Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - M-J Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
| | - J-M Sun
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
| |
Collapse
|
2
|
van Beek EJR, Ahn JS, Kim MJ, Murchison JT. Validation study of machine-learning chest radiograph software in primary and emergency medicine. Clin Radiol 2023; 78:1-7. [PMID: 36171164 DOI: 10.1016/j.crad.2022.08.129] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Revised: 07/20/2022] [Accepted: 08/08/2022] [Indexed: 01/07/2023]
Abstract
AIM To evaluate the performance of a machine learning based algorithm tool for chest radiographs (CXRs), applied to a consecutive cohort of historical clinical cases, in comparison to expert chest radiologists. MATERIALS AND METHODS The study comprised 1,960 consecutive CXR from primary care referrals and the emergency department (992 and 968 cases respectively), obtained in 2015 at a UK hospital. Two chest radiologists, each with >20 years of experience independently read all studies in consensus to serve as a reference standard. A chest artificial intelligence (AI) algorithm, Lunit INSIGHT CXR, was run on the CXRs, and results were correlated with those by the expert readers. The area under the receiver operating characteristic curve (AUROC) was calculated for the normal and 10 common findings: atelectasis, fibrosis, calcification, consolidation, lung nodules, cardiomegaly, mediastinal widening, pleural effusion, pneumothorax, and pneumoperitoneum. RESULTS The ground truth annotation identified 398 primary care and 578 emergency department datasets containing pathologies. The AI algorithm showed AUROC of 0.881-0.999 in the emergency department dataset and 0.881-0.998 in the primary care dataset. The AUROC for each of the findings between the primary care and emergency department datasets did not differ, except for pleural effusion (0.954 versus 0.988, p<0.001). CONCLUSIONS The AI algorithm can accurately and consistently differentiate normal from major thoracic abnormalities in both acute and non-acute settings, and can serve as a triage tool.
Collapse
Affiliation(s)
- E J R van Beek
- Edinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK; Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, UK.
| | | | | | - J T Murchison
- Department of Radiology, Royal Infirmary of Edinburgh, Edinburgh, UK
| |
Collapse
|
3
|
Lee HH, Kim I, Kim UK, Choi SS, Kim TY, Lee D, Lee Y, Lee J, Jo J, Lee YT, Lee HJ, Kim SJ, Ahn JS. Therapeutic effiacy of T cells expressing chimeric antigen receptor derived from a mesothelin-specific scFv in orthotopic human pancreatic cancer animal models. Neoplasia 2021; 24:98-108. [PMID: 34954452 PMCID: PMC8718570 DOI: 10.1016/j.neo.2021.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 12/20/2021] [Indexed: 11/16/2022]
Abstract
Novel CAR T cells targeting mesothelin (MSLN) expressed on pancreatic cancer cells were developed to overcome the limit of the clinical efficacy of CAR T cell therapy for pancreatic cancer patients. Optimal single-chain variable fragments (scFv) binding to MSLN were selected based on the binding activity and the functional effectiveness of various scFv containing CAR-expressing T cells. Engineered MSLN CAR T cells showed successful anti-tumor activity specific to MSLN expression level. Furthermore, MSLN CAR T cells were evaluated for the anti-cancer efficacy in orthotopic mouse models bearing pancreatic cancer cells, MIA Paca-2, MSLN-overexpressed MIA Paca-2 or endogenously MSLN-expressing AsPC-1. Mice were randomized into control, mock treated, MS501 BBz treated, MS501 28z treated or MS501 28BBz treated group. Mice were monitored by weekly IVIS imaging and tumors were harvested and analyzed by immunohistochemical analyses. MSLN CAR T cells produced the therapeutic effect in orthotopic animal models with complete remission in significant number of mice. Histopathological analysis indicated that CD4+ and CD8+ MSLN CAR T cells infiltrated pancreatic tumor tissue and led to cancer cell eradication. Our results demonstrated the anti-tumor efficacy of MSLN CAR T cell therapy against pancreatic cancer, suggesting its therapeutic potential.
Collapse
Affiliation(s)
- Hyeon Ho Lee
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Irene Kim
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Un Kyo Kim
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Suk San Choi
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Tae Yang Kim
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Dahea Lee
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Youngeun Lee
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Jaehee Lee
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Jinhui Jo
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Young-Tae Lee
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea
| | - Ho Jeong Lee
- Platbio, Inc, Platbio, Inc, #1501, Ace Gwanggyo Tower2, 91 Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon, Gyeonggido 16229, Republic of Korea
| | - Sun Jin Kim
- Platbio, Inc, Platbio, Inc, #1501, Ace Gwanggyo Tower2, 91 Changnyong-daero 256beon-gil, Yeongtong-gu, Suwon, Gyeonggido 16229, Republic of Korea.
| | - Jong Seong Ahn
- GC Cell, Inc, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin, Gyeonggido 16924, Republic of Korea.
| |
Collapse
|
4
|
Abstract
OBJECTIVE This retrospective study investigated the nature and severity of venom-induced consumption coagulopathy (VICC) and determined the clotting factors involved in VICC in patients after envenomation by South Korea's snakes. Additionally, we studied the effectiveness of antivenom for the treatment of VICC after envenomation. METHODS Included patients were divided into three groups according to the severity of VICC (no VICC, partial VICC, and complete VICC). Data, including changes in coagulation parameters during hospitalization and clotting factors at presentation, were collected and analyzed. RESULTS One hundred nineteen patients who presented at our emergency department within 3 h after snake envenomation were included. VICC developed in 34 patients (27 patients with partial VICC and 7 patients with complete VICC). Two of 34 patients with VICC required blood transfusions. Five patients with complete VICC had an undetectable fibrinogen concentration at presentation. Three patients with complete VICC had an unmeasurable INR and aPTT within 24 h. The median times of the most extreme values were 10 h for INR, 12 h for aPTT, and 16 h for fibrinogen after presentation in the VICC group. The D-dimer concentration peaked at a median of 63.5 h after presentation. The activities of factors II and X were significantly reduced in the complete VICC group (factor II: 88 (84-99.3)% in the non-VICC group vs. 69 (49.5-83.5)% in the complete VICC group; factor X:94 (83-102) in the non-VICC group vs. 70 (66.5-79.8)% in the complete VICC group), while there was no difference in factor V activity at presentation. The time from bite to first antivenom administration did not correlate with the time course and most extreme concentrations for fibrinogen and D-dimer within the VICC groups. DISCUSSION AND CONCLUSION VICC occurs in approximately one-quarter of snakebite patients in South Korea; however, VICC itself does not appear to lead to clinical deterioration. Fibrinogen is an early diagnostic maker for complete VICC. Clotting factors II and X are involved in VICC. Future investigations should explore the mechanism of VICC from Korean snakebites and the effect of antivenom on VICC.
Collapse
Affiliation(s)
- J M Moon
- Department of Emergency Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.,Department of Emergency Medicine, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea
| | - B J Chun
- Department of Emergency Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.,Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
| | - Y S Cho
- Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
| | - J C Kim
- Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
| | - Y J Koo
- Department of Agricultural Chemistry, Chonnam National University, Gwangju, Republic of Korea
| | - K H Park
- Department of Emergency Medical Rescue, Nambu University, Gwangju, Republic of Korea.,Department of Medical science, Chonnam National University Graduate School, Gwangju, Republic of Korea
| | - S D Lee
- Department of Emergency Medicine in Trauma Center, Wonkwang University Hospital, Iksan, Republic of Korea
| | - J S Ahn
- Department of Internal Medicine, Chonnam National University Hwasun Hospital, Jeollanam-do, Republic of Korea
| | - D K Kim
- Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
| | - S J Ryu
- Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
| |
Collapse
|
5
|
Park YH, Lee SJ, Cho EY, La Choi Y, Lee JE, Nam SJ, Yang JH, Shin JH, Ko EY, Han BK, Ahn JS, Im YH. Clinical relevance of TNM staging system according to breast cancer subtypes. Ann Oncol 2019; 30:2011. [PMID: 31408085 DOI: 10.1093/annonc/mdz223] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/09/2023] Open
|
6
|
Ahn HK, Park S, Hyun SH, Park K, Lee E, Kim JY, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im YH, Park YH. Abstract P3-08-12: PIK3CA mutations in breast cancer: Mutational landscape and clinical implications in ER+/HER2- subtype. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p3-08-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: PIK3CA mutation is one of the most frequent genomic alterations in breast cancer. We evaluated PIK3CA mutational status including spatial and temporal heterogeneity, clinical characteristics and prognostic impact focused on ER+/HER2- subtype.
Methods: We performed targeted ultra-deep sequencing (CancerSCAN™) of breast cancer tissue in a prospective cohort. Burden of disease was assessed by metabolic tumor volume(MTV) in 18F-FDG-PET scan. Association with clinical characteristics or survival were tested in ER+/HER2- subtype, using Chi square test or Kaplan-Meier method.
Results: PIK3CA analyses were performed in 1274 breast cancer specimens from 1091 patients. 957 patients had early breast cancer. PIK3CA alterations were found in 397 patients(36.3%), and frequency of PIK3CA mutation was significantly lower in triple negative breast cancer(19.0%), compared with 40.4% in ER+/HER2-, 40.9% in ER+/HER2+, and 45.2% in ER-/HER2+ subtype(p<0.0001). 158 patients had more than two biopsies. Among 92 patients with second biopsy within one month, 11%(10/92) had spatial heterogeneity of PIK3CA mutation. After neoadjuvant chemotherapy, 10%(3/30) of patients had change of PIK3CA mutational status. Serial biopsy at time of recurrence revealed loss or gain of PIK3CA mutation in 10 out of 59 patients (17%). In ER+/HER2- subtype, PIK3CA had a trend toward longer distant disease free survival without statistical significance. In patients with stage IV ER+/HER2- disease, PIK3CA hotspot mutations were associated with significant longer overall survival(OS) (71.0 vs. 37.8 months, p=0.048) and better progression free survival(PFS) at 1st line palliative treatment (37.7 vs. 9.4 months, p = 0.0004). Frequency of symptomatic recurrence, recurrence as oligometastases, and specific metastatic sites were not associated with PIK3CA mutational status, except that bone metastases at first distant metastases was less prevalent in patients with PIK3CA hotspot mutations(35.6% vs. 53.8% in PIK3CA wt, p=0.048). Metabolic tumor volume(MTV) at time of first distant metastases was not associated with presence of PIK3CA mutation.
Conclusion: We observed variations in PIK3CA mutational status in more than 10% of patients with >1 repeated biopsy. In stage IV ER+/HER2- disease, PIK3CA hotspot mutation seemed to be associated with longer PFS and OS, however metabolic tumor burden was not associated with PIK3CA alterations.
Citation Format: Ahn HK, Park S, Hyun SH, Park K, Lee E, Kim J-Y, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im Y-H, Park YH. PIK3CA mutations in breast cancer: Mutational landscape and clinical implications in ER+/HER2- subtype [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-08-12.
Collapse
Affiliation(s)
- HK Ahn
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SH Hyun
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - K Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - E Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J-Y Kim
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SJ Nam
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SW Kim
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JE Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SK Lee
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JH Yu
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JS Ahn
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y-H Im
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - YH Park
- Gachon University Gil Medical Center, Incheon, Korea; Samsung Advanced Institute for H Ealth Sciences & Tehnology, Seoul, Korea; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
7
|
Kim JY, Park KH, Park WY, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im YH, Park YH. Abstract P1-09-11: Prognostication of genetic alterations of ESR 1 in estrogen receptor positive metastatic breast cancers using targeted ultra-deep sequencing data analysis. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-09-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Genetic alteration of Estrogen Receptor 1(ESR1) gene have been associated with acquired endocrine resistance and occurred in about 20% of endocrine resistant estrogen receptor(ER)-positive metastatic breast cancer(MBC). Mutations in ligand binding domain of ESR1 lead to constitutive activity of the ER without ligand estrogen and stimulated down stream cell growth signal. Therefore, ESR1 ligand binding domain alteration is known resistant mechanism of aromatase inhibitor. Among these ESR1 mutations, Y537S, one of the ligand binding domain mutations, caused ER antagonist, fulvestrant resistance. Therefore, assessment of ESR1 mutation in ER-positive MBC had significant benefit to further precision medicine for MBCs. In this study, we explored to identify the frequency and type of ESR1 genetic alterations of ER-positive MBC.
Methods: We performed targeted ultra-deep sequencing (CancerSCAN™) using BC tissue specimens. This sequencing was covered entire coding area of ESR1 gene and also detected copy number alteration and translocation of ESR1.
Results: Targeted ultra-deep sequencing of ESR1 was performed using 990 BC tissues. Of 990 tissue samples, 341(34.5%) were MBCs. Of MBCs, 112(11.3%) were ER-positive and human epidermal growth factor receptor 2(HER2)-negative BCs. In ER-positive HER2-negative MBCs (N=112), 21 ESR1 genetic alterations were identified in 19 BCs (17.0%). Nineteen were single nucleotide variats (SNVs) and three were copy number (CN) amplification. Most commonly detected single nucleotide variant (SNV) was D538G (6 of 19, 31.6%) followed by Y537N, Y537S, V382I (4, 2 and 2 cases, respectively). Three mutations occurred in non-ligand binding domain (G415V, V392I and P79A). Two BC samples harbored two ESR1 mutations, respectively (Y537S and D538G, L536P and Y537N). In terms of treatment, 11 of 12 patients with ER-positive MBC harboring ESR1 mutation received palliative endocrine therapies. Eight patients received aromatase inhibitor and two patients received tamoxifen. One patient received letrozole plus palbociclib. In 2 MBCs with Y537S mutation, progression free survival (PFS) of endocrine therapy was 1.4 and 5.3 months. MBCs with D538G had 12.3months of PFS (range, 5.3-23.7(months)) and BCs harboring another ligand binding domain mutations (Y537N, L536H and L536P) had 15.7months of PFS of endocrine therapy (range, 8.4-17.3(months)). BC with mutation observed in non-lignand binding domain had short PFS (1.8 (V392I) and 2.7 (P79A) months, respectively). In terms of ESR1 CN amplification, patients could not receive endocrine therapy because their BCs rapidly progressed and extensive distant metastases were occurred within 3 months after curative surgery.
Conclusion: In this exploratory study, ESR1 genetic alterations were detected in about 20% of ER-positive MBC. The type of genetic alterations varied including SNVs, CNAs. Each locus of ESR1 mutation predicted endocrine resistance. In addition, we might suggest that ESR1 CN amplification is prognostic marker of ER-positive BCs.
Citation Format: Kim J-Y, Park KH, Park W-Y, Nam SJ, Kim SW, Lee JE, Lee SK, Yu JH, Ahn JS, Im Y-H, Park YH. Prognostication of genetic alterations of ESR 1 in estrogen receptor positive metastatic breast cancers using targeted ultra-deep sequencing data analysis [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-09-11.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - KH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W-Y Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SJ Nam
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SW Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JE Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - SK Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JH Yu
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - JS Ahn
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y-H Im
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - YH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
8
|
Kim JY, Jung HH, Lim JE, Cho EY, Lee SK, Yu JH, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im YH. Abstract P4-08-30: Prognostication of immune related gene expression in patients with triple negative breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-08-30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: To date, the role of immunotherapy with check point inhibitors and/or vaccines in the treatment of breast cancer (BC) is still debating, and the main focus of immunotherapy in BC is on triple negative subtype as a target population in many ongoing clinical trials. Translational research into identifying predictive and prognostic immune biomarkers is of particular clinical relevance, but, there are currently no definite prognostic and predictive immune biomarkers in BC, especially in triple negative breast cancer(TNBC). We investigated the expression profiles of immune genes in patients with TNBC to identify the prognostic value of immune genes in search of clinical implications.
Methods : We investigated expression profiles of 770 pan-cancer immune related genes using the nCounter mRNA expression assay (NanoString®) from paraffin-embedded tumor tissues in 200 patients diagnosed as TNBC who received curative surgery at Samsung Medical Center from 2000 to 2004. We analyzed the relationship between stage adjusted level of gene expressions and patients' survival outcomes using Cox regression model.
Results: Of 770 genes, 186 genes were selected from univariate analysis with clinical stage adjustment. In multivariate analysis using Cox regression, expressions of CD1B, CD45, CD53, CT45A1, GTF3C1, IL11RA, IL1RN, LRRN3, MAPK1, NEFL, PRKCE, SPACA3 and RANKL were associated with distant recurrence free survival (p<0.05, respectively). Among these 13 genes, expression of MAPK1, NEFL, CD45, SPACA3 and RANKL were correlated with favorable outcome in terms of distant recurrence free survival (p<0.05, respectively). In terms of overall survival, C3, IL1RL1, IL1RN, IL7 and PRKCE were associated with poor prognosis (p<0.05, respectively) and expression of SAA1 CXCL9 and RANKL resulted in favorable outcome (p<0.05, respectively).
Table 1ParameterParameter EstimateStandard Errorp-valueHazard Ratio95% Confidence Interval(a) distant recurrence free survival Stage2.487350.680570.000312.0293.169, 45.661CD1B1.141910.2753<.00013.1331.826, 5.374CD531.531650.34851<.00014.6262.336, 9.159CT45A10.426110.134210.00151.5311.177, 1.992GTF3C11.193110.579720.03963.2971.059, 10.271IL11RA1.671120.461750.00035.3182.151, 13.146IL1RN0.980280.24657<.00012.6651.644, 4.321LRRN31.424170.28742<.00014.1542.365, 7.297MAPK1-0.542740.258240.03560.5810.35, 0.964NEFL-1.12170.335610.00080.3260.169, 0.629PRKCE2.378340.49659<.000110.7874.076, 28.549CD45-2.736780.43154<.00010.0650.028, 0.151SPACA3-0.745930.272270.00610.4740.278, 0.809RANKL-1.288920.2976<.00010.2760.154, 0.494(b) overall survival Stage1.359280.497810.00633.8931.468, 10.329C30.329830.150350.02831.3911.036, 1.867CXCL9-0.379190.100680.00020.6840.562, 0.834IL1RL10.679360.262940.00981.9731.178, 3.303IL1RN0.437130.172370.01121.5481.104, 2.171IL70.507280.206250.01391.6611.109, 2.488PRKCE0.835340.272910.00222.3061.35, 3.936SAA1-0.564250.13449<.00010.5690.437, 0.74RANKL-0.604990.234510.00990.5460.345, 0.865
Conclusion: High expression of IL1RN, PRKCE were associated with short distant recurrence free survival and overall survival in patients with TNBCs who received curative surgery. In contrast, RANKL expression resulted in prolonged distant recurrence free survival and overall survival.
Citation Format: Kim J-Y, Jung HH, Lim JE, Cho EY, Lee SK, Yu JH, Lee JE, Kim SW, Nam SJ, Park YH, Ahn JS, Im Y-H. Prognostication of immune related gene expression in patients with triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-08-30.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - HH Jung
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - JE Lim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - EY Cho
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - SK Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - JH Yu
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - JE Lee
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - SW Kim
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - SJ Nam
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - YH Park
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - JS Ahn
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| | - Y-H Im
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea
| |
Collapse
|
9
|
Kim JY, Park K, Park WY, Nam SJ, Kim SW, Lee JE, Lee SK, Jung HH, Yu JH, Ahn JS, Im YH, Park YH. Abstract P6-09-08: Identification of ESR1 mutation in breast cancers using targeted ultra-deep sequencing data analysis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-09-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Estrogen Receptor 1 (ESR1) gene encodes an estrogen receptor, which regulates cell proliferation and promotes tumor progression in estrogen receptor(ER)-positive breast cancer (BC). Therefore, endocrine therapy that inhibiting ER downstream signal, is the most effective treatment strategy in ER-positive BC. However, about 25% of patients with primary disease and almost all patients with metastases will present with or eventually develop endocrine resistance. And genetic alteration of ESR1 is now identified as the endocrine resistance mechanism. However, a few data from clinical trials or public data base exists and could not reflect real world clinic. Therefore, we aimed to identify the frequency and type of ESR1 genetic alterations in BCs through this large scaled study.
Methods: We performed targeted ultra-deep sequencing (CancerSCAN™) using BC tissue specimens. This sequencing was covered entire coding area of ESR1 gene and also detected copy number alteration and translocation of ESR1.
Results: Targeted ultra-deep sequencing of ESR1 was performed using 618 BC tissues. Of 618 tissue samples, 253(40.9%) were MBCs, 362(58.6%) were early BCs (EBCs) and 3 were not identified. In terms of subtypes, 220 ER-positive BCs, 122 ER-positive and HER2-positive BCs, 119 HER2-positive and 153 triple-negative BCs (TNBCs) were included. BCs from patients under 40 year-old were 277(44.8%)(Median: 43.0, range: 23.5 -75.6). ESR1 genetic alterations were identified in 21 BCs (5 EBCs and 16 MBCs). In EBCs, 3 cases were observed in TNBCs and 2 cases were in ER-positive BCs (2.6% and 1.2%, respectively). All five EBC were treatment naïve status. Of 16 cases of ESR1 alterations in MBCs, 10 cases of ESR1 alterations were detected in ER-positive BCs (17.6%), 5cases in ER and HER2-positive BCs(6.7%) and 1 in HER2-positive BCs (1.2%). All ER-positive MBCs were treated with more than one line of endocrine therapy. Most commonly detected genetic alteration was single nucleotide variant (SNV) (15 of 21, 71.4%). Thirteen were in ligand binding domain and two cases occurred in activation function-1 (AF-1) domain (P79A and G145S). D538G and V392I were most frequently mutated loci followed by Y537N (3, 3 and 2 cases, respectively) and only metastatic ER-positive BCs harbored ESR1 activating mutation. Four copy number (CN) amplification in 2 ER-positive and 2 ER and HER2-positive BCs, one CN deletion in TNBC and one ESR1 fusion in ER and HER2-positive BC were also detected (19.0%, 4.8% and 4.8%, respectively). In frame ESR1 fusion was occurred between ESR1 and NPHS1 genes.
Conclusion: In this experimental study, ESR1 genetic alterations were frequently detected in ER-positive MBC but ER-negative or EBC also harbored. The type of genetic alterations varied including SNVs, CN alterations and translocation and ESR1-NPHS1 fusion is the novel genetic alteration that has not been reported. To identify the role of ESR1 genetic alteration in ER-negative BCs and novel translocation, further functional validation would be warranted (Clinical trials.gov Number :NCT02591966).
Citation Format: Kim J-Y, Park K, Park W-Y, Nam SJ, Kim SW, Lee JE, Lee SK, Jung HH, Yu JH, Ahn JS, Im Y-H, Park YH. Identification of ESR1 mutation in breast cancers using targeted ultra-deep sequencing data analysis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P6-09-08.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - K Park
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - W-Y Park
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - SJ Nam
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - SW Kim
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - JE Lee
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - SK Lee
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - HH Jung
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - JH Yu
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - JS Ahn
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - Y-H Im
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| | - YH Park
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Seoul, Korea; Samsung Advanced Institute for Health Sciences and Technology, Seoul, Korea
| |
Collapse
|
10
|
Lee SH, Lee JK, Ahn MJ, Kim DW, Sun JM, Keam B, Kim TM, Heo DS, Ahn JS, Choi YL, Min HS, Jeon YK, Park K. Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial. Ann Oncol 2017; 28:292-297. [PMID: 27803005 DOI: 10.1093/annonc/mdw559] [Citation(s) in RCA: 145] [Impact Index Per Article: 20.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Background Chromosomal rearrangements involving RET, which are found in about 1% of non-small cell lung cancer (NSCLC), define a unique molecular subset. We performed this study to examine the efficacy and safety of vandetanib 300 mg daily in this patient population. Patients and methods This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate. Results A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Conclusion Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.
Collapse
Affiliation(s)
- S-H Lee
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J-K Lee
- Department of Internal Medicine, Seoul National University Hospital, Seoul
| | - M-J Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - D-W Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul
| | - J-M Sun
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - B Keam
- Department of Internal Medicine, Seoul National University Hospital, Seoul
| | - T M Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul
| | - D S Heo
- Department of Internal Medicine, Seoul National University Hospital, Seoul
| | - J S Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - Y-L Choi
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - H-S Min
- Department of Pathology, Seoul National University Hospital, Seoul, Korea
| | - Y K Jeon
- Department of Pathology, Seoul National University Hospital, Seoul, Korea
| | - K Park
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| |
Collapse
|
11
|
Kim JY, Cho J, Kim H, Kang D, Jung HA, Lee SH, Bae S, Yu JH, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Guallar E, Park YH. Abstract P6-09-50: Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-09-50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction:Substantial efforts have been made to find factors associated with breast cancer (BC) recurrence and mortality after BC treatment. So far TNM stage, ER, PR, and HER2 status are considered as the major predictive markers of BC recurrence and used for treatment decision. However, most of these factors were evaluated independent from other important confounders such as age, stage, and various anti-cancer treatments because they were mostly derived from clinical trials. In Korea, up to 50% of BC patients are premenopausal women, it is not clear how age at diagnosis affect the progression and outcomes of the disease considering all known prognostic factors including TNM stage, ER, PR, and HER2 status. We aim to evaluate the impact of young age on recurrence and mortality after surgery among Korean women with BC.
Methods: This is a retrospective cohort study conducted using the data from BC registry from 2000 to 2016 at Samsung Medical Cancer, Seoul, Korea. Patients who received curative BC surgery and who had histologically-confirmed invasive BC between 2000 to 2011 were included in the study. Patients who second primary cancer or double primary cancer were excluded. Information local, regional, or distant recurrence and death until May 2016 was collected using electronic medical records and National Health Statistics. Cumulative incidence rates of distant recurrence and morality at 3-years, 5-years and 10-years were calculated using a competing-risk model. Cox proportional hazards analysis were conducted with 3 different models to take into account for potential confounding factors including age, body mass index (BMI), stage and subtype at breast cancer diagnosis, chemotherapy, radiotherapy and hormone therapy.
Results:There were 7360 BC patients with curative BC surgery between 2000 and 2011, and the average follow up duration was 75.4 months. The mean age at diagnosis was 48.4 years old (Standard deviation (SD)=±10), and 6.2% (n=459) was diagnosed younger than 35. Of total, 13.3% were stage III BC and 73.4% of patients had hormone receptor positive BC. The cumulative incidence (95%CI) of recurrence at 3, 5, and 10 years was 4.4% (3.9-4.9), 7.5% (6.8-8.2), and 14.8% (12.9-16.7) respectively. The incidence of mortality at 3, 5, and 10 years was 1.8% (1.5-2.1), 3.8% (3.3-4.3), and 10.2% (9.1-11.5) respectively. Patients who were diagnosed BC under 35 years of age had 2.14 (95% confidence interval (CI):1.74-3.10) and 1.62 (95% CI:1.02-2.56) times higher risk of distant recurrence and mortality compared to patients whose age at diagnosis were between 50 to 60 after adjusting all well-known prognostic factors including stage, subtype, and BMI at diagnosis, chemotherapy, radiotherapy and hormone therapy.
Conclusions: Young age at diagnosis (<35) was the most significant predictor on BC recurrence and mortality independently from BC stage and subtype. Further study is warranted to explain biologic background for the differences in outcomes in young women with BC.
Citation Format: Kim J-Y, Cho J, Kim H, Kang D, Jung HA, Lee S-H, Bae S, Yu JH, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im Y-H, Guallar E, Park YH. Impact of young age on recurrence and mortality after surgery in breast cancer: 15 years active surveillance [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-09-50.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - J Cho
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - H Kim
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - D Kang
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - HA Jung
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - S-H Lee
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - S Bae
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - JH Yu
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - SK Lee
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - SW Kim
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - JE Lee
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - SJ Nam
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - JS Ahn
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - Y-H Im
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - E Guallar
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| | - YH Park
- Samsung Medical Center, Seoul, Korea; Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea; Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
| |
Collapse
|
12
|
Kan Z, Ding Y, Cho S, Lee SH, Powell E, Jung HH, Chung W, Deng S, Choi YL, Kim J, Park WY, Vizcarra P, Fernandez-Banet J, Nichols T, Ram S, Lee SK, Kim SW, Lee JE, Ching KA, Kim JY, Ahn JS, Im YH, Nam SJ, Park YH. Abstract P1-05-15: Multi-omics and immuno-oncology profiling reveal distinct molecular signatures of young Asian breast cancers. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-05-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Breast cancers (BC) in younger, premenopausal patients (YBC) tend to be more aggressive with worse prognosis, higher chance of relapse and poorer response to endocrine therapies compared to breast cancers in older patients. The proportion of YBC (age ≤ 40) among BC in East Asia is estimated to be 16-32%, significantly higher than the 7% reported in Western countries. To characterize the molecular bases of Asian YBC, we have performed whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) on tumor and matched normal samples from 134 Korean BC patients consisting of 74 YBC cases (age ≤ 40) and 60 OBC cases (age > 40). We then performed comparison analyses and integrative analyses with the TCGA BC cohort consisting of 1,116 tumors from primarily Caucasian patients, also grouped by age into YBC (age ≤ 40), IBC (40 < age ≤ 60) and OBC (age > 60).
Somatic mutation prevalence analysis identified 7 significantly mutated genes and the same top three genes – TP53, GATA3 and PIK3CA – were reported by the TCGA BC study. To identify differentially expressed (DE) genes and pathways in YBCs vs. OBCs, we performed logistic regression analyses while controlling for the confounding effects of tumor purity and stage. We were surprised to see a significant overlap in DE pathways between a comparison of adjacent normal tissues in younger vs. older TCGA cohorts and a comparison of YBC vs. OBC tumors, indicating that normal tissue compartment could contribute to observed differences between bulk tumors. To separately examine molecular signatures from tumor, stroma and normal compartments, we used non-negative matrix factorization (NMF) analyses to virtually dissect bulk tumor expression data and identified 14 factors including 3 factors associated with normal tissues, 1 factor associated with stroma and 1 factor associated with tumor infiltrating lymphocytes (TIL). Integrative analyses of tumor associated factors and DE pathways revealed that estrogen response, endocrine therapy resistance, and oxidative phosphorylation pathways are up-regulated in YBCs compared to OBCs while cell cycle and proliferation pathways are up-regulated in Asian OBCs. Interestingly, many immune and inflammation pathways correlated with the TIL factor were significantly upregulated in OBCs vs. YBCs. Using gene expression signatures representing distinct immune cell types, we classified our cohort into four subtypes of varying TIL activities and observed significant enrichment of the TIL-high subtype in OBCs compared to YBCs. These observations were confirmed by IHC analyses of four TIL markers (CD45, CD4, CD8 and CD163) in 120 tumors.
To our knowledge, this is the first large-scale multi-omics study of Asian breast cancer and would significantly contribute to the compendium of molecular data available for studying young breast cancers. The major landmarks in the molecular landscape looked similar across BCs of different ethnicities and ages, however, we have identified a number of distinguishing molecular characteristics associated with Asian YBC. The sources for some signatures were further traced to non-tumor intrinsic compartments, indicating that tumor microenvironment may play potentially important roles in driving the carcinogenesis of young breast cancers.
Citation Format: Kan Z, Ding Y, Cho S, Lee S-H, Powell E, Jung HH, Chung W, Deng S, Choi Y-l, Kim J, Park W-Y, Vizcarra P, Fernandez-Banet J, Nichols T, Ram S, Lee SK, Kim SW, Lee JE, Ching KA, Kim J-Y, Ahn JS, Im Y-H, Nam SJ, Park YH. Multi-omics and immuno-oncology profiling reveal distinct molecular signatures of young Asian breast cancers [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-05-15.
Collapse
Affiliation(s)
- Z Kan
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - Y Ding
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - S Cho
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - S-H Lee
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - E Powell
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - HH Jung
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - W Chung
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - S Deng
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - Y-l Choi
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - J Kim
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - W-Y Park
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - P Vizcarra
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | | | - T Nichols
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - S Ram
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - SK Lee
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - SW Kim
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - JE Lee
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - KA Ching
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - J-Y Kim
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - JS Ahn
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - Y-H Im
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - SJ Nam
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| | - YH Park
- Pfizer Inc., San Diego, CA; Samsung Medical Center, Seoul, Korea
| |
Collapse
|
13
|
Park YH, Im SA, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Ahn JS, Kim TY, Lee KH, Kim SB, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH. Abstract OT1-01-12: A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-01-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Metastatic breast cancer (MBC) is an incurable disease and is needed to improve effective chemotherapy. Paclitaxel plus Gemcitabine (PG) combination chemotherapy is one of the preferred chemotherapeutic regimens for patients with MBC, and was found to be proper as a maintenance chemotherapy regimen with survival benefit and feasible toxicity profile. Eribulin mesylate is a non-taxane inhibitor of microtubule dynamics of the halichondrin class of antineoplastic drugs. A recent pooled analysis of two phase II studies with eribulin showed improved overall survival in in various patient subgroups with advanced/metastatic breast cancer who had previously received an anthracycline and a taxane. Furthermore, eribulin may have rational benefit compared with paclitaxel in terms of neurotoxicity. Therefore, Eribulin plus Gemcitabine (EG) combination chemotherapy may have less neurotoxocity comparing to PG.
Trial Design: Prospective randomized phase 2, open-label, two-arm, multi-center study comparing EG chemotherapy with PG chemotherapy for patients with HER-2 negative MBC as first-line chemotherapy.
Eligibility Criteria: Histologically confirmed breast cancer patients, at least 19 years of age, with no prior history of chemotherapy for metastatic, recurrent breast cancer with evaluable lesions (as per RECIST, 1.1) who have adequate hematologic, renal, and hepatic function. Patients either may or may not have a prior anthracycline containing regimen. Prior hormonal therapy as a treatment of metastatic disease is allowed.
Specific Aims:
The primary efficacy endpoint of the trial is Progression-Free Survival (PFS). The secondary efficacy endpoints are: Time to Treatment Failure (TTF); Overall Survival (OS); neuropathic scale (FACT for Taxane QOL assessment); toxicity; duration of response; Objective Response Rate (ORR); Clinical Benefit Rate. The exploratory endpoint of the study includes pharmacogenetic profile.
Statistical Methods:
The initial sample size of the present study was determined based on the data derived from a previous trial on PG maintenance chemotherapy design; 6-month PFS is 70% for PG chemotherapy. This design was hypothesized that EG chemotherapy would not be inferior to PG chemotherapy. Thus, estimated PFS for each arm is 70%. Based on this estimate, we would plan to recruit a total of 100 patients (50 per arm). Considering drop-out rate of 10%, total 112 MBC patients planned to be enrolled.
Present Accrual and Target Accrual:Enrollment has been completed as of March, 2016 with a target enrollment of 112 patients.
Contact information:Kyung Hae Jung MD, Ph.D. khjung@amc.seoul.kr
ClinicalTrials.gov Identifier: NCT02263495.
Citation Format: Park YH, Im S-A, Sohn JH, Lee KS, Chae YS, Lee KH, Kim J-H, Im Y-H, Ahn JS, Kim T-Y, Lee K-H, Kim S-B, Ahn J-H, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH. A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer as first-line chemotherapy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-12.
Collapse
Affiliation(s)
- YH Park
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - S-A Im
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - JH Sohn
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - KS Lee
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - YS Chae
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - KH Lee
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - J-H Kim
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - Y-H Im
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - JS Ahn
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - T-Y Kim
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - K-H Lee
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - S-B Kim
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - J-H Ahn
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - GM Kim
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - IH Park
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - SJ Lee
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - HS Han
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - SH Kim
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| | - KH Jung
- Samsung Medical Center; Seoul National University Hospital; Yonsei Cancer Center; National Cancer Center; Kyungpook National University Medical Center; Chungbuk National University Hospital; Seoul National University Bundang Hospital; Asan Medical Center
| |
Collapse
|
14
|
Kim JY, Park D, Jung HH, Bae SY, Yu JH, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH, Park YH. Abstract P1-02-11: Clinical utility of serial monitoring of circulating tumor DNA (ctDNA)in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-02-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Circulating tumor DNA (ctDNA) is a new biomarker which could guide further treatment. Characterization of tumor mutation profiles is required for informed choice of therapy, given that biological agents target specific pathways and effectiveness may be modulated by specific mutations. It would have clinical utility for neoadjuvant setting also. Thus, we assess the potency of ctDNA to predict tumor response to neoadjuvant chemotherapy(NAC) in locally advanced breast cancer(LABC).
Methods: We performed targeted deep sequencing of 30 plasma DNAs and 10 matched germline DNAs from 10 LABC patients. Serial plasma DNAs were collected at diagnosis, after 1st NAC and curative surgery. For the target enrichment, we designed RNA baits covering a total of ~202kb regions of human genome including a total of 83 cancer-related genes. We constructed the sequencing libraries according to the optimized protocol that we recently reported and sequenced on Illumina HiSeq2500 aiming a mean sequencing depth of ~10,000. After excluding unmapped reads, PCR duplicates and off-target reads, the coverage depths for plasma DNA and germline DNA samples were 2,627x and 4,833x on average, respectively. NAC response was measured by residual cancer burden(RCB) score, calculated as a continuous index combining pathologic measurements of primary tumor and nodal metastases for prediction of distant relapse-free survival.
Results: We analyzed ctDNA and primary tumor tissues from 10 patients with LABC scheduled NAC followed by operation in Samsung Medical Center. Of ten LABCs, one excluded from analysis because of angiosarcoma of breast. Five samples were triple-negative breast cancers (BCs), 2 were HER2 positive BCs and others were ER positive BCs. In tumor response, 1 patient had pathologic complete response (pCR), 1 had RCB class I, 4 and 3 patients did RCB class II and III.
Of 83 genes, in analysis of ctDNA at BC diagnosis, we found 2 to 6 mutations in each samples and 3 mutations were detected averagely. Most common mutation was TP53 (6 patients), followed by PIK3CA mutation. By measuring these mutations in serial ctDNA, we found that ctDNA had disappeared after first cycle of NAC in patient with pCR. In two patients with RCB class I, ctDNA had decreased by more than 10 percent (the level of ctDNA(pg/ml): 455.9 to 30.4, 5.8 to 0.0) of primary plasma sample after first NAC. Two patients increased level of ctDNA had tumor response with RCB class III and one patient had distant tumor recurrence within 3 months after curative surgery. However, correlation between the level of ctDNA and initial stage was not observed.
Patient No.Initial stageSurgical stageRCB scoreRCB classct DNA at diagnosis (pg/5ml)ctDNA after 1st NAG (pg/5ml)Tumor recurrence12A11.3331455.930.4No22B00pCR446.60.0No33B2A1.31515.80.0No42A12.132246.255.4No52B11.7972107.811.6No63B3A4.09033401.15075.5Yes73A2B3.92235088.68536.7No
Conclusions: This preliminary result suggests that serial monitoring of ctDNA would be a potiential surrogate marker to predict tumor response and recurrence during NAC in LABC patients. Further results with long-term outcomes are warranted.
Citation Format: Kim J-Y, Park D, Jung HH, Bae SY, Yu JH, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im Y-H, Park YH. Clinical utility of serial monitoring of circulating tumor DNA (ctDNA)in patients with neoadjuvant chemotherapy (NAC) for locally advanced breast cancer (LABC) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-02-11.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - D Park
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - HH Jung
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - SY Bae
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - JH Yu
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - SK Lee
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - SW Kim
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - JE Lee
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - SJ Nam
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - JS Ahn
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - Y-H Im
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| | - YH Park
- Samsung Medical Center, Seoul, Korea; Samsung Genome Institute, Samsung Medical Center, Seoul, Korea; Biomedical Research Institute, Samsung Medical Center, Seoul, Korea; SAIHST, Sungkyunkwan University, Seoul, Korea
| |
Collapse
|
15
|
Ahn JS, Sinn DH, Son HJ, Gwak GY. Letter: Helicobacter pylori-related non-alcoholic fatty liver disease with concomitant metabolic syndrome as risk factor for colorectal neoplasia - authors' reply. Aliment Pharmacol Ther 2017; 45:577-578. [PMID: 28074505 DOI: 10.1111/apt.13911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/08/2022]
Affiliation(s)
- J S Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - D H Sinn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H J Son
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.,Center for Health Promotion, Samsung Medical Center, Seoul, Korea
| | - G-Y Gwak
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
16
|
Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung SH, Gu S, Rhee PL, Paik SW, Son HJ, Gwak GY. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017; 45:345-353. [PMID: 27859470 DOI: 10.1111/apt.13866] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/19/2016] [Revised: 09/15/2016] [Accepted: 10/27/2016] [Indexed: 12/14/2022]
Abstract
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is associated with colorectal neoplasia. Yet, NAFLD ranges from simple steatosis to steatohepatitis with advanced fibrosis. AIM To investigate the risk of colorectal neoplasia according to the presence and severity of NAFLD. METHODS A total of 26 540 asymptomatic adults who underwent same day first-time colonoscopy and abdominal ultrasonography as a health check-up programme were analysed. NAFLD was diagnosed by ultrasonography. Advanced colorectal neoplasia was defined as an invasive cancer or adenoma that was at least 10 mm in diameter, had high-grade dysplasia, or had villous histological characteristics or any combination thereof. RESULTS NAFLD patients had a higher prevalence of any colorectal neoplasia (38.0% vs. 28.9%) and advanced colorectal neoplasia (2.8% vs. 1.9%) compared to those without NAFLD. In a multivariable model adjusted for age, sex, smoking, alcohol, body mass index, first-degree family history of colorectal cancer, aspirin use and metabolic factors, the odd ratios comparing patients with NAFLD to those without were 1.10 [95% confidence interval (CI): 1.03-1.17] for any colorectal neoplasia and 1.21 (95% CI: 0.99-1.47) for advanced colorectal neoplasia. When NAFLD patients were further stratified according to the non-invasive parameters of liver disease severity, the risk of any colorectal neoplasia or advanced colorectal neoplasia was higher for those with severe liver diseases than those with mild liver diseases. CONCLUSIONS The presence and severity of NAFLD were closely associated with any colorectal neoplasia and advanced colorectal neoplasia, suggesting that clinicians should be aware of the increased risk of colorectal neoplasia in patients with NAFLD.
Collapse
Affiliation(s)
- J S Ahn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - D H Sinn
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y W Min
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S N Hong
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H S Kim
- Biostatistics and Bioinformatics Center, Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea
| | - S-H Jung
- Biostatistics and Bioinformatics Center, Samsung Cancer Research Institute, Samsung Medical Center, Seoul, Korea
| | - S Gu
- Biostatistics and Clinical Epidemiology Center, Samsung Medical Center, Seoul, Korea
| | - P-L Rhee
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - S W Paik
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H J Son
- Center for Health Promotion, Samsung Medical Center, Seoul, Korea
| | - G-Y Gwak
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
17
|
Ahn JS, Li J, Chen E, Kent DG, Park HJ, Green AR. JAK2V617F mediates resistance to DNA damage-induced apoptosis by modulating FOXO3A localization and Bcl-xL deamidation. Oncogene 2016; 35:2235-46. [PMID: 26234675 DOI: 10.1038/onc.2015.285] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2015] [Revised: 05/28/2015] [Accepted: 06/22/2015] [Indexed: 12/21/2022]
Abstract
The JAK2V617F mutation is found in most patients with a myeloproliferative neoplasm (MPN). This gain-of-function mutation dysregulates cytokine signaling and is associated with increased accumulation of DNA damage, a process likely to drive disease evolution. JAK2V617F inhibits NHE-1 upregulation in response to DNA damage and consequently represses Bcl-xL deamidation and apoptosis, thus giving rise to inappropriate cell survival. However, the mechanism whereby NHE-1 expression is inhibited by JAK2V617F is unknown. In this study, we demonstrate that the accumulation of reactive oxygen species (ROS) in cells expressing JAK2V617F compromises the NHE-1/Bcl-xL deamidation pathway by repressing NHE-1 upregulation in response to DNA damage. In JAK2V617F-positive cells, increased ROS levels results from aberrant PI3K signaling, which decreases nuclear localization of FOXO3A and decreases catalase expression. Furthermore, when compared with autologous control erythroblasts, clonally derived JAK2V617F-positive erythroblasts from MPN patients displayed increased ROS levels and reduced nuclear FOXO3A. However, in hematopoietic stem cells (HSCs), FOXO3A is largely localized within the nuclei despite the presence of JAK2V617F mutation, suggesting that JAK2-FOXO signaling has a different effect on progenitors compared with stem cells. Inactivation of FOXO proteins and elevation of intracellular ROS are characteristics common to many cancers, and hence these findings are likely to be of relevance beyond the MPN field.
Collapse
Affiliation(s)
- J S Ahn
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
| | - J Li
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
| | - E Chen
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
| | - D G Kent
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
| | - H J Park
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
| | - A R Green
- Cambridge Institute for Medical Research and Wellcome Trust/MRC Stem Cell Institute, University of Cambridge, Cambridge, UK
- Department of Haematology, University of Cambridge, Cambridge, UK
- Department of Haematology, Addenbrooke's Hospital, Cambridge, UK
| |
Collapse
|
18
|
Lee JK, Kang D, Choi EK, Kong S, Lee SK, Lee JE, Han W, Park YH, Ahn JS, Im YH, Noh DY, Nam SJ, Cho J. Abstract P1-10-31: Impact of increased physical activities after diagnosis on fatigue and overall pain during cancer treatment: A prospective cohort study. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Existing evidence strongly suggests that exercise is not only safe but also feasible during cancer treatment. Physical activity is recommended for improving multiple post-treatment adverse effects on bone health, muscle strength, and other quality-of-life measures. Yet, limited evidence exists regarding effect of increased physical activity after diagnosis on symptoms management of breast cancer patients.
Methods
A total of 422 patients were recruited from July 2010 to July 2011 at two cancer hospitals in Seoul, Korea. Physical activity in sports (PAS) was assessed using Minnesota Leisure Time Physical Activity Questionnaire before and 2 weeks, 3-, 6-, 12-, 24- and 36-months after diagnosis. Physical symptoms including fatigue, pain, arm symptom, and insomnia were measured using EORTC-C30 and BR23. Growth mixture models were used to identify trajectory classes of physical activity patterns. Multivariate analysis was used to find impact of PAS on symptom management using SAS.
Results
Three distinct PAS groups were identified according to 3-year change patterns: moderate to moderate (MM): 40.8%, none to moderate (NM): 31.1% and moderate to high (MH): 28.1%. The LM and MH group increased PAS from diagnosis but it began to decrease from 1 year after diagnosis. Compared to the MM, the NM and MH reported significantly lower level of fatigue (MM:40.7, NM:32.2, MH:33.7), pain(MM:28.0, NM:25.6, MH:20.6), systemic therapy side effects (MM:26.9, NM:22.6, MH:21.8), and breast symptoms (MM:25.4, NM:21.7, MH:20.2) during active treatment (6 months after diagnosis).
Change patterns of quality of life according to trajectory groups At diagnosis2 weeks3 months6 months12 months24 months36 monthsFatigueMM31.3±1.930.2±1.935.3±2.0140.7±2.1137.8±2.1138.5±2.1141.0±2.21NM30.2±1.928.2±1.931.9±2.132.2±2.2233.6±2.135.6±2.2137.8±2.31MH28.8±2.327.4±2.233.0±2.433.7±2.51233.9±2.4136.2±2.5137.1±2.51PainMM15.1±1.531.3±1.9123.2±2.0128.0±2.0123.5±2.0122.0±2.0121.2±1.91NM15.4±1.532.4±2.023.3±2.0125.6±2.122.7±2.021.1±2.123.8±2.01MH17.2±1.828.4±2.3121.2±2.320.6±2.4219.7±2.321.1±2.318.6±2.2Systemic therapy side effectsMM16.8±1.114.3±1.2133.2±1.7126.9±1.5125.4±1.5126.2±1.6128.6±1.71NM15.0±1.114.5±1.235.2±1.7122.6±1.61222.0±1.6124.5±1.7127.7±1.81MH15.6±1.412.9±1.4134.4±2.0121.8±1.81221.8±1.7122.1±1.9124.7±2.01Breast symptomsMM13.8±1.226.4±1.6120.8±1.5125.4±1.6123.6±1.6119.2±1.7119.6±1.71NM13.0±1.224.7±1.6119.6±1.5121.7±1.61222.3±1.7119.9±1.8119.1±1.81MH16.0±1.424.1±1.8119.4±1.820.2±1.81217.8±1.8217.4±2.014.0±1.92*adjusted with age, stage, and radiotherapy 1 p<0.05 (differences from baseline within group), 2 p<0.05 (differences from MM group within time)
Conclusion
The results of the study confirmed that increased physical activity after diagnosis, even with patients who did not exercise at all before diagnosis, helps to control fatigue, pain, systemic side effects, and breast symptoms during treatment. It is necessary to find ways to promote physical activity after diagnosis and help patients to stay active during treatment.
Citation Format: Lee JK, Kang D, Choi E-K, Kong S, Lee S-K, Lee JE, Han W, Park YH, Ahn JS, Im YH, Noh D-Y, Nam S-J, Cho J. Impact of increased physical activities after diagnosis on fatigue and overall pain during cancer treatment: A prospective cohort study. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-31.
Collapse
Affiliation(s)
- JK Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - D Kang
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - E-K Choi
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S Kong
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S-K Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - JE Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - W Han
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - YH Park
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - JS Ahn
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - YH Im
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - D-Y Noh
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S-J Nam
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - J Cho
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center; Health, Behavior and Society, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Surgery, Seoul National University Hospital; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| |
Collapse
|
19
|
Kim JY, Ahn T, Jung HH, Park K, Do IG, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im YH. Abstract P2-08-19: Prognostication of HER family gene expression collaborate with ESR1 expression in patients with triple negative breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p2-08-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple-negative breast cancer (TNBC) consists of heterogeneous sub-population. Although many investigators made an effort to categorize and classify TNBCs using genetic expressions, it is still needed to be defined for prognostication Traditionally, HER family genes have been known to contribute mammalian glands formation and breast cancer generation as well as ESR gene. Moreover, target agents for HER family genes have been already developed. Accordingly, we investigated the expression profiles of HER family genes with ESR in patients with TNBC to categorize into sub-types and determine the prognostic value of HER family genes in search of clinical implications.
Methods : We investigated the results of the nCounter expression assay (NanoString®) for ERBB1, ERBB2, ERBB3, ERBB4 and ESR1 using mRNA extract from paraffin-embedded tumor tissues in 203 patients diagnosed as TNBC. We used the results of nCounter expression assay using 84 TNBC tissues for validation and 52 breast cancer tissues diagnosed as other subtypes to control the expression assay results of these five genes.
Results: Two-hundred and three patients were diagnosed as TNBC from 2000 to 2004 and received adjuvant chemotherapy after curative surgery. Eighty-four TNBC patients for validation set and 52 patients diagnosed as other subtypes for control set were selected from the patients diagnosed as breast cancer from 2005 to 2010 and received curative surgery. Through analyzing 5 genes using the nCounter expression profiles from 203 TNBC tissues, we found that increased expression of ERBB4 was associated with poor prognosis by survival analysis (5 year disease recurrence free survival (DRFS), low vs. high expression [cut-off: median]: 90.1% vs. 80.2%; p =.002). This trend was still remained in validation set composed of TNBC (5 year DRFS, low vs. high expression [cut-off : median]: 61.1% vs. 44.0%), whereas was not observed in other subtypes of breast cancer (44.4% vs. 80.8%). The Kaplan-Meier estimates of the rates of 5 year DRFS in the subgroups classified according to the level of 5 genes expression showed that the group of higher expression of all HER family genes and lower expression of ESR1 gene had dismal prognosis rather than other groups in patients with TNBC (5 year DRFS, this group vs. others: 50.0% vs. 88.2%; p <.001). In a multivariate Cox regression model, ERBB4 expression identified as a useful marker for predicting long-term prognosis in patients with TNBC although other HER family genes and ESR1 expressions did not predict prognosis of TNBC with statistical significance (Table 1).
Impact of the m RNA expression levels of ERBB family and ESR1 on DRFS Hazard Ratio95% CIP-valueStage <.001I1.0NA IIA1.200.40-3.57 IIB3.751.20-11.74 IIIA5.461.55-9.24 IIIC59.9214.30-251.12 EGFR .167Low1.0NA High1.690.80-3.55 ERBB2 .057Low1.0NA High0.430.18-1.03 ERBB3 .061Low1.0NA High2.200.96-5.04 ERBB4 .016Low1.0NA High2.681.20-5.95 ESR1 .113Low1.0NA High0.570.28-1.15
Conclusions: The expression profile of HER family genes could be used as a prognostic marker in patients with TNBC. Further study is needed to identify the expression profiles of HER family gene as predictive marker of HER targeting treatment in patients with TNBC.
Citation Format: Kim J-Y, Ahn T, Jung HH, Park K, Do I-G, Kil WH, Kim SW, Lee JE, Nam SJ, Ahn JS, Park YH, Im Y-H. Prognostication of HER family gene expression collaborate with ESR1 expression in patients with triple negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P2-08-19.
Collapse
Affiliation(s)
- J-Y Kim
- Samsung Medical Center, Seoul, Korea
| | - T Ahn
- Samsung Medical Center, Seoul, Korea
| | - HH Jung
- Samsung Medical Center, Seoul, Korea
| | - K Park
- Samsung Medical Center, Seoul, Korea
| | - I-G Do
- Samsung Medical Center, Seoul, Korea
| | - WH Kil
- Samsung Medical Center, Seoul, Korea
| | - SW Kim
- Samsung Medical Center, Seoul, Korea
| | - JE Lee
- Samsung Medical Center, Seoul, Korea
| | - SJ Nam
- Samsung Medical Center, Seoul, Korea
| | - JS Ahn
- Samsung Medical Center, Seoul, Korea
| | - YH Park
- Samsung Medical Center, Seoul, Korea
| | - Y-H Im
- Samsung Medical Center, Seoul, Korea
| |
Collapse
|
20
|
Lee JK, Cho J, Park SK, Kim IR, Yoon JH, Choi EK, Cho SY, Lee SK, Lee JE, Kim S, Nam SJ, Park YH, Ahn JS, Im YH. Abstract P1-10-30: Effect of mind and beauty education on body image among young breast cancer patients: A randomized controlled trial. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p1-10-30] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
The proportion of young age-onset breast cancer in Korea is relatively higher than Western countries. Young breast cancer patients are more likely to suffer from altered appearance due to cancer treatment such as breast disfiguration, hair loss, skin change and experience poor body image. This randomized controlled trial (RCT) is designed to evaluate the effect of mind and beauty education program on body image among breast cancer patients under 40-years old.
Methods
A total of 109 eligible breast cancer patients aged 18-40 years old, who had surgery and/or chemotherapy within 18 months and who reported poor body image (<66 EORTC QLQ-BR23 body image score) were recruited and randomly assigned to intervention and control group from July 2014 and April 2015 at an university-based hospital in Seoul, Korea. Intervention group received a structured 8 hours education (2 hours for 4 weeks, 1 hour for mind control and 1 hour for altered appearance management) and control group had education after outcome evaluation. Body image as primary outcome was assessed using both EORTC QLQ-BR23 and body image scale (BIS). In addition, socio-demographic characteristic, self-esteem, quality of life, anxiety, and depression were assessed. Outcomes were evaluated before the intervention, right after the intervention (visit 2), and 3 (visit 3) and 6 months (visit 4) after the intervention. T-test and intention-to-treat analysis performed to compare the outcomes of the two groups.
Results
A total of 54 and 55 patients were assigned to intervention and control group respectively with block randomization. Among the intervention group, 43 participants (79.6%) attended for more than 6 hours of education. Total 46 participants (85.2%) in intervention group and 53 participants (96.4%) in control group completed the questionnaire at visit 2.
Mean age of the study population was 35.5 years old and there were 53 (48.6%), 32 (29.3%), 23 (21.1%) stage I, II, and III breast cancer patients respectively. At baseline, none of the socio-demographic, clinical, psycho-social characteristics were different between two groups. While there was no difference with the body image at baseline between intervention (57.69±20.57) and control group (53.09±26.98) (P=0.327), intervention group reported significantly improved body image than control group (EORTC QLQ-BR23 - Intervention; 71.69±20.27 and Control; 55.97±23.07, P<0.001). The results were similar with BIS measured body image (BIS - Intervention; 17.77±6.29 and Control; 21.29±6.94, P=0.012).
Conclusion
This study provided evidence supporting that mind and body education program would be beneficial to young women with breast cancer who would suffer from low body image. Active education program and psychosocial support related to altered appearance would help young breast cancer patients to make a smooth transit when they return to usual life.
Trial registration: This study is registered in Korean Clinical Research Information Service (CRIS) with registration number KCT0001191.
Funding: This study was supported by grants from Amorepacific.
Citation Format: Lee JK, Cho J, Park SK, Kim I-R, Yoon J-H, Choi E-K, Cho S-Y, Lee S-K, Lee JE, Kim S, Nam S-J, Park YH, Ahn JS, Im YH. Effect of mind and beauty education on body image among young breast cancer patients: A randomized controlled trial. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-10-30.
Collapse
Affiliation(s)
- JK Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - J Cho
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - SK Park
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - I-R Kim
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - J-H Yoon
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - E-K Choi
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S-Y Cho
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S-K Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - JE Lee
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S Kim
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - S-J Nam
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - YH Park
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - JS Ahn
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| | - YH Im
- Cancer Education Center, Samsung Comprehensive Cancer Center, Samsung Medical Center, Sungkyunkwan University School of Medicine; Health Science and Technology, SAHIST, Sungkyunkwan University; Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine; Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine
| |
Collapse
|
21
|
Abstract
OBJECTIVE The purpose of the study was to evaluate the effect of bleaching on teeth with white spot lesions. METHODS AND MATERIALS Carious lesions with standardized whiteness were produced on the buccal and lingual surfaces of human premolars by pH cycling. Specimens were subjected to four experimental conditions (n=20/group) as follows: group 1, control; group 2, caries formation followed by remineralization using fluoride-containing casein phosphopeptide-amorphous calcium phosphate (CPP-ACP; Tooth Mousse Plus, GC, Tokyo, Japan); group 3, caries formation followed by bleaching using 10% carbamide peroxide; and group 4, caries formation followed by both bleaching and remineralization. The CIE L(*)a(*)b(*) color values were measured with a spectroradiometer, the mineral content was measured with electron probe microanalysis (EPMA) on the cross-sectional surface of each specimen, and the Knoop hardness test was carried out along the EPMA scan line. Two-way analysis of variance was performed with Tukey post hoc comparison. RESULTS The change in the CIE color values was not significantly different between the caries-formed (ΔE(*)=7.03) and the bleached enamel (ΔE(*)=7.60). Bleaching of the carious enamel extended the whiteness (ΔE(*)=3.38) without additional mineral loss (p<0.05). The remineralization treatment significantly increased the calcium (Ca), phosphate (P), and fluoride content of the subsurface lesion area (p<0.05). The cross-sectional microhardness values correlated well with the Ca and P content (R>0.80). CONCLUSIONS Bleaching reduced the color disparities between sound and carious enamel without deteriorating the chemical and mechanical properties. The application of CPP-ACP paste enhanced mineral deposition in the subsurface lesion area of carious enamel.
Collapse
|
22
|
Sun JM, Choi YL, Ji JH, Ahn JS, Kim KM, Han J, Ahn MJ, Park K. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol 2015; 26:161-166. [PMID: 25355724 DOI: 10.1093/annonc/mdu504] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND Once regarded as a smoker's disease, small-cell lung cancer (SCLC) has been occasionally detected in never-smokers as smoking rates decrease worldwide. We investigated the clinical and genetic characteristics of SCLC in never-smokers. PATIENTS AND METHODS Patients diagnosed with SCLC were grouped into smokers and never-smokers. The clinical outcomes of the two groups were compared. For SCLC in never-smokers, somatic mutation profiling was carried out using the AmpliSeq™ Cancer Hotspot Panel v2 and semiconductor sequencing technology. Epidermal growth factor receptor (EGFR) mutation was confirmed by PNAClamp™. RESULTS In total, 391 SCLC patients treated over a 5-year period were analyzed. Fifty patients (13%) were never-smokers. The median overall survival was 18.2 months in never-smokers and 13.1 months in smokers (P = 0.054). Never-smoking history was independently a good prognostic factor [hazard ratio = 0.645, 95% confidence interval (CI) 0.456-0.914], as were limited disease (HR = 0.372, 95% CI 0.294-0.471), and lower age (HR = 0.709, 95% CI 0.566-0.888). The objective response rates to first-line etoposide/cisplatin therapy were similar between never-smokers and smokers (75% versus 81%). Of 28 genetically evaluable never-smokers, EGFR mutations were detected in four cases (two L858R, one deletion in exon 19, and one G719A). Other mutations were in TP53 (n = 26), RB1 (n = 7), PTEN (n = 5), MET (n = 4), and SMAD4 (n = 3). CONCLUSIONS Never-smokers with SCLC are increasingly prevalent and have a better prognosis than smokers with SCLC in Korea. Our study warrants further investigation in this group.
Collapse
Affiliation(s)
- J-M Sun
- Division of Hematology-Oncology, Department of Medicine
| | - Y-L Choi
- Division of Hematology-Oncology, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J H Ji
- Division of Hematology-Oncology, Department of Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
| | - J S Ahn
- Division of Hematology-Oncology, Department of Medicine
| | - K-M Kim
- Division of Hematology-Oncology, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - J Han
- Division of Hematology-Oncology, Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
| | - M-J Ahn
- Division of Hematology-Oncology, Department of Medicine
| | - K Park
- Division of Hematology-Oncology, Department of Medicine.
| |
Collapse
|
23
|
Zhou W, Oh J, Li W, Kim DW, Yang MH, Jang JH, Ahn JS, Lee SH, Na M. Chemical constituents of the Korean endangered species Rhododendron brachycarpum. BIOCHEM SYST ECOL 2014. [DOI: 10.1016/j.bse.2014.06.003] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
24
|
Li XZ, Park BK, Yan CG, Choi JG, Ahn JS, Shin JS. Effect of alcohol fermented feed on lactating performance, blood metabolites, milk Fatty Acid profile and cholesterol content in holstein lactating cows. Asian-Australas J Anim Sci 2014; 25:1546-52. [PMID: 25049515 PMCID: PMC4093031 DOI: 10.5713/ajas.2012.12248] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2012] [Revised: 07/27/2012] [Accepted: 06/26/2012] [Indexed: 11/27/2022]
Abstract
A feeding experiment with 40 lactating Holstein cows and 4 dietary treatments was conducted to investigate supplementation with different levels of alcohol fermented feed to the TMR on lactating performance, blood metabolites, milk fatty acid profile and cholesterol concentration of blood and milk. Forty Holstein lactating cows (106±24 d post-partum; mean±SD) were distributed into four groups and randomly assigned to one of four treatments with each containing 10 cows per treatment. The treatment supplemented with TMR (DM basis) as the control (CON), and CON mixed with alcohol-fermented feeds (AFF) at a level of 5%, 10% and 15% of the TMR as T1, T2 and T3, respectively. Dry matter intake and milk yield were not affected by supplementation of AFF. An increased 4% FCM in the milk occurred in cows fed T3 diet compared with CON, while T1 and T2 diets decreased 4% FCM in a dose dependent manner. Supplementation of AFF increased the concentration of albumin, total protein (TP), ammonia, and high density lipoprotein-cholesterol in serum compared with CON. In contrast, supplementation with AFF clearly decreased concentration of blood urea nitrogen (BUN) and total cholesterol (TC) compare with CON. AFF supplementation increased the proportion of C18:1n9 and C18:2n6 compared to CON. A decrease in the concentration of saturated fatty acid (SFA) for T1, T2 and T3 resulted in an increased unsaturated fatty acid (USFA) to SFA ratio compared to CON. Concentration of cholesterol in milk fat was reduced in proportion to the supplemental level of AFF. Feeding a diet supplemented with a moderate level AFF to lactating cows could be a way to alter the feed efficiency and fatty acid profile of milk by increasing potentially human consumer healthy fatty acid without detrimental effects on feed intake and milk production. A substantially decreased cholesterol proportion in milk induced by supplementation AFF suggests that alcohol fermented feed may improve milk cholesterol levels without any negative effects in lactating cows.
Collapse
Affiliation(s)
- X Z Li
- Department of Animal Science, College of Agriculture Science, Yanbian University, Yanji, JiLin, 13302, China
| | - B K Park
- Nonghyup Feed Co., LTD., Seoul 134-763, Korea
| | - C G Yan
- Department of Animal Science, College of Agriculture Science, Yanbian University, Yanji, JiLin, 13302, China
| | - J G Choi
- Deahan Livestock and Feed Co., LTD. BukSung-Dong, 1-Ka, Chung-Ku, Incheon 400-201, Korea
| | - J S Ahn
- Department of Animal Science, College of Agriculture Science, Yanbian University, Yanji, JiLin, 13302, China
| | - J S Shin
- Department of Animal Science, College of Agriculture Science, Yanbian University, Yanji, JiLin, 13302, China
| |
Collapse
|
25
|
Park YH, Jung HA, Choi MK, Chang W, Choi YL, Do IG, Ahn JS, Im YH. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer 2013; 110:384-91. [PMID: 24346286 PMCID: PMC3899777 DOI: 10.1038/bjc.2013.757] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Revised: 10/27/2013] [Accepted: 10/31/2013] [Indexed: 01/28/2023] Open
Abstract
BACKGROUND The aim of this study was to investigate the role of human epidermal growth factor receptor (HER3) and PTEN expression in patients with HER2-overexpressing metastatic breast cancer (MBC). METHODS One hundred twenty-five MBC patients who were treated with taxane plus trastuzumab chemotherapy as first-line therapy were included in this analysis. Immunohistochemical (IHC) staining with HER3 and PTEN antibodies were conducted retrospectively. RESULTS Patients who had negative HER3 staining (62.4%) had a better progression-free survival (PFS) than did those who had positive HER3 staining (P=0.001; median PFS, 21 vs 11 months). Patients who had a PTEN score >20 (78.1%) showed longer PFS than did those with a PTEN score ≤20 (P=0.006; median PFS, 13 vs 9 months). Patients who had a PTEN score >20 exhibited a longer overall survival (OS) than did those with a PTEN score ≤20 (P=0.005; median OS, 48 vs 25 months). HER3 negativity and PTEN loss were identified as independent risk factors for PFS. PTEN loss was identified as an independent risk factor for OS. CONCLUSION HER3 and PTEN expressions may be predictive markers, and PTEN expression may be a predictive and prognostic biomarker for trastuzumab treatment in HER2-positive MBCs.
Collapse
Affiliation(s)
- Y H Park
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - H A Jung
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - M K Choi
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - W Chang
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y L Choi
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - I-g Do
- Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - J S Ahn
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - Y-H Im
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| |
Collapse
|
26
|
Abstract
SUMMARY
Objective
The aim of this study is to evaluate the reproducibility of working casts of a digital impression system by comparing them with the original, virtual, and rapid prototyping casts.
Materials and Methods
A total of 54 cast sets in clinically stable occlusion were used. They were scanned by an iTero intraoral scanner and converted into STL format virtual casts. Rapid prototyping casts and polyurethane casts were fabricated from the iTero milling system based on the virtual casts. Several horizontal and vertical measurements were performed from the four types of casts, that is, original stone casts, virtual casts, rapid prototyping casts, and polyurethane casts of iTero. Measurement error, intraclass correlation coefficient (ICC), and differences among the casts were calculated and compared.
Results
Casts from iTero milling machines exhibited greater dimensional differences and lower ICC values than did other casts. In addition, many of the measurements of the iTero working casts showed statistically significant differences in comparison to the three other types of casts. In contrast, there were no statistically significant differences between the virtual and original casts.
Conclusion
Virtual casts made by the iTero intraoral scanner exhibited excellent reproducibility. However, the casts from the iTero milling machine showed greater dimensional differences and lower reproducibility compared to other types of casts.
Collapse
Affiliation(s)
- YC Hwang
- Yu-Chang Hwang, DDS, MS, graduate student, Major in Dentistry, Department of Medical Science, Graduate School, Korea University, Seoul, Republic of Korea
| | - YS Park
- Young-Seok Park, BS, DDS, MSD, PhD, assistant professor, Department of Oral Anatomy, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, Republic of Korea
| | - HK Kim
- Hong-Kyun Kim, BS, MSD, graduate student, Department of Oral Anatomy, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, Republic of Korea
| | - YS Hong
- Yong Shin Hong, DDS, graduate student, Department of Oral Anatomy, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, Republic of Korea
| | - JS Ahn
- Jin-Soo Ahn, DDS, MSD, PhD, assistant professor, Department of Dental Biomaterials Science, Dental Research Institute and School of Dentistry, Seoul National University, Seoul, Republic of Korea
| | - JJ Ryu
- Jae-Jun Ryu, DDS, PhD, professor, Korea University, Department of Dentistry, Seoul National University, Seoul, Republic of Korea
| |
Collapse
|
27
|
Abstract
We recently demonstrated that pain-sensing neurons in the trigeminal system can be selectively anesthetized by co-application of QX-314 with the TRPV1 receptor agonist, capsaicin (QX cocktail). Here we examined whether this new anesthetic strategy can block the neuronal changes in the brainstem following molar tooth extraction in the rat. Adult male Sprague-Dawley rats received infiltration injection of anesthetic 10 min prior to lower molar tooth extraction. Neuronal activation was determined by immunohistochemistry for the proto-oncogene protein c-Fos in transverse sections of the trigeminal subnucleus caudalis (Sp5C). After tooth extraction, c-Fos-like immunoreactivity (Fos-LI) detected in the dorsomedial region of bilateral Sp5C was highest at 2 hrs (p < .01 vs. naïve ipsilateral) and declined to pre-injury levels by 8 hrs. Pre-administration of the QX cocktail significantly reduced to sham levels Fos-LI examined 2 hrs after tooth extraction; reduced Fos-LI was also observed with the conventional local anesthetic lidocaine. Pulpal anesthesia by infiltration injection was confirmed by inhibition of the jaw-opening reflex in response to electrical tooth pulp stimulation. Our results suggest that the QX cocktail anesthetic is effective in reducing neuronal activation following tooth extraction. Thus, a selective pain fiber 'nociceptive anesthetic' strategy may provide an effective local anesthetic option for dental patients in the clinic.
Collapse
Affiliation(s)
- B Badral
- Pain Cognitive Function Research Center, Dental Research Institute and Department of Neurobiology & Physiology
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer 2013; 109:1482-7. [PMID: 23963141 PMCID: PMC3776982 DOI: 10.1038/bjc.2013.467] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2013] [Revised: 07/12/2013] [Accepted: 07/21/2013] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The mammalian target of rapamycin (mTOR) pathway is dysregulated in small-cell lung cancer (SCLC) and everolimus is an oral mTOR inhibitor. METHODS This phase-1b study assessed everolimus safety at the levels of 2.5, 5, or 10 mg once daily in combination with paclitaxel (175 mg m(-2)) once every 3 weeks in previously treated SCLC patients. The primary end point was to determine the maximum tolerated dose of everolimus. RESULTS Among 21 enrolled patients, common drug-related adverse events were anaemia, neutropenia, thrombocytopenia, pain, hyperglycemia, and stomatitis. Out of 11 evaluable patients treated with everolimus at the level of 5 mg, 1 patient experienced dose-limiting toxicity (DLT) of grade 4 febrile neutropenia and grade 3 thrombocytopenia. The other two DLTs (grade 4 thrombocytopenia and grade 3 hyperglycemia) occurred in two out of three patients receiving everolimus 10 mg. The overall objective response rate was 28%. CONCLUSION Everolimus showed an acceptable safety profile and preliminary antitumour activity at the dose of 5 mg once daily when combined with 3-weekly paclitaxel 175 mg m(-2) in patients with SCLC.
Collapse
Affiliation(s)
- J M Sun
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Park BM, Ahn JS, Lee JB, Won YH, Yun SJ. Chronic active Epstein-Barr virus infection-associated hydroa vacciniforme-like eruption and Behçet's-like orogenital ulcers. Dermatology 2013; 226:212-6. [PMID: 23751255 DOI: 10.1159/000348709] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 02/04/2013] [Indexed: 11/19/2022] Open
Abstract
The cutaneous manifestations of chronic active Epstein-Barr virus (EBV) infection can be diverse. Among them, hydroa vacciniforme-like eruption is one of the best-known features. Although rare, mucosal ulcers have been reported to be associated with EBV as a result of primary infection or immune suppression. We describe a 65-year-old female with recurrent necrotic papulovesicles on the face and both arms for 2 years. She also complained of recurrent oral and genital mucosal ulcers developing simultaneously with skin eruptions. They appeared periodically during the spring and summer and were triggered or aggravated by sun exposure. Skin biopsies from the face and genitalia showed identical findings with dense lymphocytic infiltrations. In addition, in situ hybridization revealed EBV-positive lymphoid cells in both specimens. To our knowledge, this is the first case of serologically and pathologically proven chronic active EBV infection presenting hydroa vacciniforme-like eruption and orogenital ulcers at the same time in one patient.
Collapse
Affiliation(s)
- B M Park
- Department of Dermatology, Chonnam National University Medical School, Gwangju, South Korea
| | | | | | | | | |
Collapse
|
30
|
Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol 2013; 24:2088-92. [PMID: 23592701 DOI: 10.1093/annonc/mdt140] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND We compared late thoracic radiotherapy (TRT) with early TRT in the treatment of limited-disease small-cell lung cancer (LD-SCLC). PATIENTS AND METHODS Patients with LD-SCLC received four cycles of etoposide plus cisplatin every 21 days. Patients were randomly assigned to receive either TRT administered concurrently with the first cycle (early TRT) or the third cycle (late TRT) of chemotherapy. The primary end point was complete response rate. RESULTS Two hundred twenty-two patients were randomly assigned.Late TRT was not inferior to early TRT in terms of the complete response rate (early v late; 36.0% v 38.0%). Other efficacy measures including overall survival [median, 24.1 v 26.8 months;hazard ratio (HR) 0.93; 95% CI = 0.67–1.29] and progression free survival (median, 12.4 v 11.2 months; HR 1.09; 95%CI = 0.80–1.48) were not different between two arms. No statistical difference was noted in the pattern of treatment failures.However, neutropenic fever occurred more commonly in the early TRT arm than the late TRT arm (21.6% v 10.2%; P = 0.02) [corrected]. CONCLUSION In LD-SCLC treatment, TRT starting in the third cycle of chemotherapy seemed to be noninferior to early TRT, and had a more favorable profile with regard to neutropenic fever.
Collapse
Affiliation(s)
- J-M Sun
- Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol 2013; 24:1630-9. [PMID: 23393122 DOI: 10.1093/annonc/mds649] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Given the more comorbidities with a decline in physiologic reserve, it can be challenging to make appropriate treatment decisions in the elderly. PATIENTS AND METHODS Here, we prospectively evaluated and compared the health-related quality of life (HRQOL) of patients aged ≥ 65 with aged <65 who were treated with a postoperative chemotherapy for completely resected stage Ib, II or IIIa non-small-cell lung cancer (NSCLC). Either four cycles of paclitaxel (Taxol)-carboplatin (PC) or vinorelbine-cisplatin (NP) was used. The HRQOL was assessed with EORTC QLQ-C30 and EORTC QLQ-LC13. RESULTS Between October 2008 and October 2011, a total of 139 patients (aged <65, n = 73; ≥ 65, n = 66) were enrolled, and 127 (91.4%) completed the questionnaire. Overall, the quality of life (QOL) in elderly patients did not significantly deteriorate with adjuvant chemotherapy and the time trend of QOL in elderly patients was similar to that of younger patients. Although the elderly suffered from increased treatment-related adverse events involving sore mouth, peripheral neuropathy and alopecia compared with the baseline, the same time trends were also observed in younger group. The mean dose intensities (MDIs) for PC and NP regimen were not significantly different between the two age groups. CONCLUSIONS Postoperative chemotherapy did not substantially reduce HRQOL in elderly NSCLC patients, and HRQOL during and after adjuvant chemotherapy did not significantly differ by age.
Collapse
Affiliation(s)
- S Park
- Division of Hematology-Oncology, Department of Medicine, Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Lee S, Jung HH, Park YH, Ahn JS, Im YH. Abstract P4-06-13: Effects of Statin on triple-negative breast cancer (TNBC) with Ets-1 overexpression. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p4-06-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Triple negative breast cancer (TNBC) is diagnosed accounting for approximately 15–20% of all breast cancer diagnoses and an aggressive clinical phenotype characterized by lack of expression of estrogen receptor (ER) and progesterone receptor (PR) as well as the absence of human epidermal growth factor receptor-2 (HER-2) overexpression. Because of its expression profile, TNBC is not amenable to treatment with hormone therapy or the anti-HER2 monoclonal antibody trastuzumab, and systemic treatment options are limited to cytotoxic chemotherapy. At present, there is not a clear, proven effective single agent that targets a defining vulnerability in TNBC.
The proto-oncogene Ets-1 is a member of the Ets family of transcription factors which share a unique DNA binding domain, the Ets domain. Ets proteins are targets for phosphorylation in response to stimulation by a variety of different growth modulators, including intracellular calcium, activators of protein kinase C pathways, growth factors and cytokines. The importance Ets genes in human carcinogenesis is supported by the observations that Ets genes have altered expression patterns, are chromosomally amplified or deleted, or are located at translocation breakpoints in leukemia and solid tumors. In model systems, increased expression of Ets-1 was found to be associated with enhanced angiogenesis and the invasive phenotype. Studies in breast cancer cell lines have implicated Ets-1 in the progression of breast cancer.
The present study was conducted to better understand the molecular mechanisms underlying statin-induced suppression associated with transcription factor Ets-1 overexpressed TNBC.
Methods: We evaluated the anti-tumor effects of simvastatin on TNBC cells using a MTT assay, invasion assay, siRNA transfection, western blotting and xenograft study which were used to address the role of Ets-1 activity and the Erk/Akt pathway on the effect of simvastatin.
Results: We demonstrated that the expression of Ets-1 was increased particular in TNBC cells among various breast cancer cell lines and the simvastatin statistically significantly enhanced antitumor activity in Ets-1 overexpressed TNBC cells. In a mouse model, the growth of Ets-1 expressed TNBC xenograft tumors was statistically significantly inhibited when simvastatin was treated. Furthermore, our data demonstrated for the first time that simvastatin inhibited the growth of TNBC cells by inhibiting Ets-1 activity via Erk and Akt pathway in a dose-dependent manner.
Conclusion: Our results suggest that the inhibition of Ets-1 acitivity via Erk and Akt pathway may be a novel mechanism by which simvastatin suppresses the growth of TNBC cells. The ability of simvastatin to induce cell death via Ets-1, as well as its ability to downregulate signaling through Ras/Raf/MEK/Erk and PI3K/Akt pathway, suggested translational value. Exploitation of this activity might include a combination of Ras/Raf/MEK/Erk or PI3K/Akt/mTOR inhibitors and simvastatin to induce cell death or the combination of simvastatin in these signaling pathways. Further preclinical and clinical studies are warranted to further investigate the application of simvastatin for the treatment of TNBC.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-06-13.
Collapse
|
33
|
Im SA, Oh DY, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Kim JH, Lee MH, Lee KE, Kim HJ, Lee KH, Han SW, Kim SY, Kim SB, Im YH, Ro J, Park HS. Abstract PD09-05: Single nucleotide polymorphism of XRCC1 which participates in DNA repair mechanism predicts clinical outcome in relapsed or metastatic breast cancer patients treated with S1 and oxaliplatin chemotherapy: Results from multicenter prospective study (TORCH_KCSG BR07-03). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd09-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: S1 and oxaliplatin (SOX) combination chemotherapy is an effective regimen in anthracycline and taxane pretreated metastatic breast cancer (MBC) patients with manageable toxicities (KCSG BR07-03, SABCS 2011 #Abst P3-16-06). The aim of this study was to investigate the association of the single nucleotide polymorphisms (SNPs) and clinical outcome in MBC treated with SOX chemotherapy.
Patients and Methods: A total of 87 MBC patients previously treated with or resistant to anthracycline and taxane chemotherapy were enrolled in this prospective multicenter trial. The patients received S-1 80mg/m2/day (day 1–14) and oxaliplatin 130 mg/m2 (day 1) every 3 weeks till progression. Among the 87 patients, 77 patients were available for SNP analysis. Germline DNA from peripheral blood (PB) mononuclear cells was extracted. SNPs in 4 genes from pathways that may influence cellular sensitivity to S1 and oxaliplatin (TS, ERCC, XPD, and XRCC) were genotyped from PB sample using PCR-restriction fragment length polymorphism.
Results: Overall response rate (RR) was 38.5% (95% CI: 27.7–49.3) and disease control rate was 67.9% (95% CI:57.5–78.3) to SOX. Median time-to-progression (TTP) and overall survival (OS) were 6.0 mo (95% CI: 5.1–6.9 mo) and 19.4 mo (95% CI: not estimated), respectively. XRCC1 Arg194Trp SNP which participates in DNA repair mechanism showed correlation with the clinical outcome. RR was tend to higher in XRCC1 Arg194Trp CC genotype compared with CT or TT genotype (50.0 % vs 35.1% or 12.5%, P = 0.121). TTP of patients with CC genotype in XRCC1 Arg194Trp was significantly longer than the TTP of patients with CT or TT genotype (median TTP: 6.4 mo in CC, 5.9 mo in CT, 3.0 mo in TT, P = 0.007) as well as overall survival (OS) (median OS: not reached in CC, 13.9 mo in CT, 7.1 mo in TT, P = 0.006). After adjusting for hormone receptor status, performance status, and visceral involvement, prognostic value of XRCC1 Arg194Trp SNP remained significant (Hazard Ratio=1.322 and 4.484, P = 0.016). Other SNPs were not significantly associated with survival or toxicities.
Conclusion: XRCC1 Arg194Trp SNP is associated with clinical outcome of MBC patients treated with SOX chemotherapy. Further studies of the relationship between germline polymorphisms in XRCC1 and functional mechanism researches are warranted.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD09-05.
Collapse
Affiliation(s)
- S-A Im
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - D-Y Oh
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - B Keam
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - KS Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J-H Ahn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J Sohn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - JS Ahn
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - JH Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - MH Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - KE Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - HJ Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - K-H Lee
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - SW Han
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - S-Y Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - SB Kim
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - Y-H Im
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - J Ro
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| | - H-S Park
- Seoul National University Hospital, Seoul, Korea; National Cancer Center, Goyang, Korea; Asan Medical Center, Seoul, Korea; Yonsei University College of Medicine, Severance Hospital, Seoul, Korea; Samsung Medical Center, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Korea; Inha University Hospital, Incheon, Korea; Ewha Womans University Medical Center, Seoul, Korea; Hallym University Sacred Heart Hospital, Anyang, Korea; Kyung-Hee University Hospital, Seoul, Korea; Soon Chun Hyang University Hospital, Seoul, Korea
| |
Collapse
|
34
|
Park YH, Im SA, Cho EY, Ahn JH, Woo SY, Kim S, Keam B, Lee JE, Han W, Nam SJ, Park IA, Noh DY, Yang JH, Ahn JS, Im YH. Abstract P2-05-20: Validation and comparison of CS-IHC4 score with a nomogram based on Ki67 index, Adjuvant! Online, and St. Gallen risk stratification to predict recurrence in early Hormone Receptor (HR)-positive breast cancers. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p2-05-20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Recently, the information in the IHC score was reported to be similar to that in the 21-gene Genomic Health recurrence score (GHI-RS). The aim of this study is to develop a nomogram based on Ki67 index to predict recurrence and to validate the nomogram by comparison with CS-IHC4 as well as Adjuvant! Online and St. Galen risk stratification. In addition, we validated our nomogram with external cohort.
Methods: We retrospectively analyzed the clinicopathologic characteristics and outcomes of 1,070 postoperative HR-positive breast cancer patients between 2004 and 2007 at the Samsung Medical Center to determine recurrence-free survival (RFS). We constructed nomogram using Cox proportional hazard model and validated externally in a cohort of 1,028 at Seoul National University Hospital. A prognostic model that used classical variables, Adjuvant! Online, St. Gallen risk stratification, and the four IHC markers (IHC4 score) were created and assessed in our cohort by LR-χ2 test using the bootstrapping method.
Results: Nomogram showed an area under the receiver operating characteristic curve (AUC) of 0.70 (95% CI, 0.62–0.75) in the training set. The validation set showed a good discrimination with an AUC of 0.65 (95% CI, 0.58–0.72). In LR-χ2 test, the nomogram score was found to be more informative than the IHC4 with CS (LR-χ2 4.0539 [df1], 95% CI; 0.1038–8.004 for CS-IHC4 + nomogram score vs. CS-IHC4).
Prognostic significance was more prominent in N1 diseases than in the others (LR-χ2 4.199, 95% CI; 1.496–6.902 for CS-IHC4 + nomogram score vs. CS-IHC4).
However, Adjuvant! Online and St. Galen risk stratification did not show any definitive additional prognostic value.
Conclusions: We developed and validated a nomogram based on Ki67 index in external patients' cohort. It was compared with CS-IHC4 in our patients' cohort in early HR-positive breast cancers. This study implicates the amount of prognostic information contained in the nomogram is superior to that in the CS-IHC4 score.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P2-05-20.
Collapse
Affiliation(s)
- YH Park
- Samsung Medical Center; Seoul National University College of Medicine
| | - S-A Im
- Samsung Medical Center; Seoul National University College of Medicine
| | - EY Cho
- Samsung Medical Center; Seoul National University College of Medicine
| | - JH Ahn
- Samsung Medical Center; Seoul National University College of Medicine
| | - SY Woo
- Samsung Medical Center; Seoul National University College of Medicine
| | - S Kim
- Samsung Medical Center; Seoul National University College of Medicine
| | - B Keam
- Samsung Medical Center; Seoul National University College of Medicine
| | - JE Lee
- Samsung Medical Center; Seoul National University College of Medicine
| | - W Han
- Samsung Medical Center; Seoul National University College of Medicine
| | - SJ Nam
- Samsung Medical Center; Seoul National University College of Medicine
| | - IA Park
- Samsung Medical Center; Seoul National University College of Medicine
| | - D-Y Noh
- Samsung Medical Center; Seoul National University College of Medicine
| | - JH Yang
- Samsung Medical Center; Seoul National University College of Medicine
| | - JS Ahn
- Samsung Medical Center; Seoul National University College of Medicine
| | - Y-H Im
- Samsung Medical Center; Seoul National University College of Medicine
| |
Collapse
|
35
|
Bang OY, Jin KS, Hwang MN, Kang HY, Kim BJ, Lee SJ, Kang S, Hwang YK, Ahn JS, Sung KW. The Effect of CXCR4 Overexpression on Mesenchymal Stem Cell Transplantation in Ischemic Stroke. Cell Med 2012; 4:65-76. [PMID: 26858855 DOI: 10.3727/215517912x647172] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
There is no doubt that the therapeutic efficacy of mesenchymal stem cells (MSCs) needs improvement. SDF-1 (chemokine for MSC homing) and its receptor CXCR4 play a critical role in the migration of MSCs in ischemia. We investigated the effects of the therapeutic application of MSCs transfected to overexpress CXCR4 using an adenoviral construct in the rat stroke model. Both flow cytometry and Western blot analysis indicated that the level of CXCR4 expression was low in naive hMSCs but was consistently high in CXCR4-hMSCs. In vivo migration test using the transwell system showed that the degree of migration was increased in CXCR4-hMSCs compared with the naive hMSCs and was completely blocked by treatment with AMD3100, an antagonist of the CXCR4 receptor. Compared with rats that received naive MSCs, behavioral recovery was more pronounced in rats that received CXCR4-hMSCs (p = 0.023). An immunohistochemistry study using human nuclear antibody (NuMA) showed that the migration of hMSCs in the ischemic boundary zone was increased after 3 days of injection of CXCR4-hMSCs compared with after injection of naive hMSCs. In addition, polymerase chain reaction was performed to assess the biodistribution of human-specific DNA outside the brain after intravenous injection of hMSCs. The expression of human-specific DNA was increased in the lungs of rats receiving naive MSCs, whereas the human-specific DNA expression was increased in the brain of rats receiving CXCR4-hMSCs. Our results indicate that MSCs transfected with the CXCR4 gene expression cassette may be useful in the treatment of cerebral infarction and may represent a new strategy to enhance the efficacy of MSC therapy.
Collapse
Affiliation(s)
- Oh Young Bang
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| | - Kyung Sil Jin
- † Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| | - Mi Na Hwang
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| | - Ho Young Kang
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| | - Byoung Joon Kim
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| | - Sang Jin Lee
- ‡ Genitourinary Cancer Branch, National Cancer Center , Goyang , South Korea
| | - Sangmee Kang
- § Cancer Therapeutics Team II, Mogam Biotechnology Research Institute , Yongin , South Korea
| | - Yu Kyeong Hwang
- § Cancer Therapeutics Team II, Mogam Biotechnology Research Institute , Yongin , South Korea
| | - Jong Seong Ahn
- ¶ Cell Therapy Division, GCLabCell Corp. , Yongin , South Korea
| | - Ki Woong Sung
- † Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
| |
Collapse
|
36
|
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. P5-01-11: Small Node-Negative (T1b-cN0) Invasive Hormone Receptor (HR)-Positive Breast Cancers: Is There a Population Which Might Have Benefit from Adjuvant Chemotherapy? Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p5-01-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
It has been widely accepted that small and node-negative breast cancers have an excellent prognosis and do not generally have clinical benefit from adjuvant chemotherapy. Recently, the role of adjuvant chemotherapy for small node negative breast cancers has been justified in some high-risk patients, which include HER2−positive and triple negative breast cancers. However, the question has been raised as to whether there are some patients who might have benefit from adjuvant chemotherapy in small node-negative HR-positive breast cancers. According to the current 2011 NCCN guideline, 21-gene RT-PCR assay can be considered for tumor size of more than 0.5 cm in HR-positive, HER2−negative cancers. In cases of high recurrence score (≥ 31), adjuvant chemotherapy in addition to endocrine therapy is recommended as category 2B. Because gene array cannot routinely be used in clinical practice and has not been validated in prospective randomized trials and the usefulness of it still needs to be defined, it would be better if there were valuable markers to determine risk for relapse in this setting. We hypothesized that there could be a population who might have clinical benefit from adjuvant chemotherapy in this small node-negative HR-positive tumors.
Patients and Methods
We retrospectively analyzed the clinicopathologic characteristics and outcomes of 538 postoperative HR-positive (ER-positive and/or PgR-positive) T1b-cN0 breast cancer patients between 2004 and 2007 at the Samsung Medical Center. We performed Cox regression multivariate analysis for relapse using variables from univariate analysis by log-rank test for relapse.
Results: The median age at diagnosis was 46 years (range, 22–79). During the median 60.5 months of follow-up, the 5-year recurrence rate was 5.2%. Anthracycline-based adjuvant chemotherapy was administered to 44.8% of the patients. Adjuvant endocrine and radiation treatment were administered to 94.6% and 63.7% of the patients. There were significant differences according to histologic grade (HG), Ki67 index, and age of less than 35 years in univariate analyses regarding RFS (p=0.003, p<0.0001, and p=0.003, respectively by log-rank test). There was no significant difference according to tumor size of subcentimeter (< 1cm) (p=0.826). In Cox regression multivariate analysis, high Ki67 index and young age of less than 35 years were identified as independent risk factors for relapse (p<0.0001 for Ki67 index and 0.015 for young age). The high risk patients (n=24, 4.5%) who have high Ki67 index (more than 75%, 4+) or young age of less than 35 and more than 50% of Ki67 index showed better RFS with statistical significance for anthracycline-containing adjuvant chemotherapy (p=0.029).
Conclusion: A patients’ population may exist who have clinical benefit from adjuvant chemotherapy in T1b-cN0 HR-positive breast cancer patients. Ki67 index and age are useful as valuable surrogate markers to predict recurrence and to have benefit from adjuvant chemotherapy in this population.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P5-01-11.
Collapse
|
37
|
Im SA, Oh DY, Lee KS, Ahn JH, Shon J, Ahn JS, Kim JH, Han SW, Lee MH, Lee KE, Lee K, Kim HJ, Keam B, Kim SY, Kim SB, Im YH, Ro J, Park HS. P3-16-06: Phase II Trial of TS-1 in Combination with Oxaliplatin (SOX) in Patients with Metastatic Breast Cancer (MBC) Previously Treated with Anthracycline and Taxane Chemotherapy [TORCH] [Korean Cancer Study Group (KCSG) BR07-03]. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p3-16-06] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Oxaliplatin, a platinum analogue, is an active drug in advanced anthracycline and taxane-pretreated breast cancer patients as a single agent and with 5-fluorouracil (5-FU) combination. TS-1 was developed by the scientific theory of both potentiating antitumor activity of 5-FU and reducing gastrointestinal toxicity. This trial was performed to evaluate the efficacy and safety of TS-1 in combination with oxaliplatin in metastatic breast cancer (MBC) patients previously treated with anthracycline and taxane chemotherapy.
Methods: Between October 2007 and October 2009, MBC patients were enrolled in this prospective multicenter trial. Eligible criteria included age ≥18 years, at least one measurable lesion, prior treatment with anthracycline and taxane chemotherapy, and ECOG Performance Status 0–2. TS-1 40 mg/m2 b.i.d. on days 1–14 with oxaliplatin 130 mg/m2 on day 1 were administered every 3 weeks till disease progression. Primary end-point was response rate, and secondary end-points were time-to-progression (TTP), overall survival (OS), duration of response (DOR) and toxicities. Response was evaluated every 6 weeks according to the RECIST criteria v. 1.0 and toxicity was assessed with NCICTCAE v.3.0.(ClinicalTrials.gov identifier NCT00527930).
Results: A total of 87 patients were enrolled. Median age was 48 years (range 30–71 years). Nineteen patients (21.8%) had de novo stage IV and 68 patients (78.2%) had recurrent disease. Thirty-five patients (40.2%) received two-lines of prior chemotherapy in palliative setting. Forty-eight patients (55.2%) had ≥ 3 disease sites. Fifty-four patients (62.1%) were hormone receptor positive, and 25 patients (28.7%) were triple negative. Five patients received prior anti-HER2 therapy. A total of 525 cycles were administered (median 6 cycles, range: 1 ∼ 22+ cycle). In per-protocol analysis, overall response rate was 38.5% (95% CI: 27.7−49.3) (CR 0%, PR 38.5%) and disease control rate (CR, PR, and SD) was 67.9% (95% CI: 57.5−78.3). Median TTP, OS, and DOR were 6.0 months (95% CI: 5.1−6.9 months), 19.4 months (95% CI: not estimated), 6.6 months (95% CI: 3.7−9.6 months), respectively. RR was not different by triple negativity (39.1% in TNBC vs. 38.2% in non-TNBC, P=0.361). TTP was not different according to the number of prior chemotherapy regimens. Reported grade 3 or 4 toxicities (per cycle) were neutropenia (10.3%), thrombocytopenia (5.5%), diarrhea (1.9%), vomiting (1.9%), and stomatitis (0.2%). There was no treatment-related death.
Conclusions: SOX is an effective regimen in anthracycline and taxane pretreated MBC patients with manageable toxicities.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-16-06.
Collapse
Affiliation(s)
- S-A Im
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - D-Y Oh
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - KS Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J-H Ahn
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J Shon
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - JS Ahn
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - JH Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - SW Han
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - MH Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - KE Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - K Lee
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - HJ Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - B Keam
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - S-Y Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - SB Kim
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - YH Im
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - J Ro
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| | - H-S Park
- 1Seoul National University Hospital, Seoul, Republic of Korea; National Cancer Center, Republic of Korea; Asan Medical Center, Seoul, Republic of Korea; Yonsei University College of Medicine, Severance Hospital, Seoul; Samsung Medical Center, Seoul, Republic of Korea; Seoul National University Bundang Hospital, Seongnam, Republic of Korea; Inha University Hopsital, Incheon, Republic of Korea; Ewha Womans University Medical Center, Seoul, Republic of Korea; Hanlim University Pyungchon Hospital, Pyungchon, Republic of Korea; Kyung Hee University Hopital, Seoul, Republic of Korea; Soon Chun Hyang University Hospital, Seoul, Republic of Korea
| |
Collapse
|
38
|
Park YH, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. P1-12-15: Adjuvant Trastuzumab Effect on HER2−Positive Breast Cancers According to Hormonal Receptor (HR) Status: Crosstalk between ER and EGFR/HER2 Pathway May Prevent Trastuzumab from Improving Outcomes in HER2−Positive and HR-Positive Breast Cancers. Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p1-12-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Crosstalk between growth factor receptor, especially the EGFR/HER2 pathway, and ER pathways has been associated with endocrine resistance. Thus, combination therapy targeting both ER and EGFR/HER2 signaling to block the crosstalk between these pathways and eliminate escape routes have been proven effective in both preclinical and clinical models. Anti-HER2 directed therapy has been reported to restore hormone sensitivity in HER2−positive breast cancers. Adding trastuzumab to conventional treatment has been a standard treatment of choice in HER2−positive breast cancer irrespective of hormonal receptor (HR) status. The purpose of the study is to evaluate adding effect of 1 year of trastuzumab to conventional adjuvant treatment in patients with HER2−positive breast cancer who received surgery according to HR status.
Patients and Methods: We retrospectively analyzed the clinicopathologic characteristics and outcomes of 618 postoperative HER2−positive breast cancer patients between 2001 and 2008 at the Samsung Medical Center. Most of HER2−positive patients in our institute were treated with 1 year of trastuzumab as a part of adjuvant therapy since 2007 (post-trastuzumab era) compared with 2000–2006 (pre-trastuzumab era). Clinical outcomes including recurrence-free survival (RFS) were analyzed between pre-trastuzumab and post-trastuzumab era according to HR status. We performed Cox regression multivariate analysis for relapse using variables from univariate analysis by log-rank test for relapse. Clinical presentations and clinicopathologic characteristics were evaluated at the time of recurrence between both eras.
Results: The median age at diagnosis was 46 years (range, 22–79). During the median 60.0 months of follow-up, the 5-year recurrence rate was 20.2%. The 618 patients were divided into two groups (patients who received (n=175) and did not receive (n=443) adjuvant trastuzumab). Recurrence rate was much lower in post-trastuzumab era than in pre-trastuzumab era (13.6% vs. 32.3%, p<0.0001). Improving outcomes due to adding trastuzumab in patients with HER2+ve/HR-ve patients showed significant benefit from trastuzumab throughout the follow-up period (p=0.004). However, this improving effect appeared not to be consistent with statistical significance in HER2+ve/HR+ve patients (p=0.135). The analyses were performed according to quantitative ER Allred scores in HER2+ve/ER+ve patients, the effect of adding trastuzumab appeared to be mitigated as time over without any statistical significance (p=0.975). Young age (≤35) (hazard ratio (HR) 2.4, p<0.0001), trastuzumab use (HR 0.4, p=0.001), and node positivity (HR 2.8, p<0.0001) were identified as independent prognostic factors for recurrence in Cox-regression multivariate analysis. Limiting to HER2+ve/ER+ve patients, the statistical significances of trastuzumab use as independent factors were not maintained in Cox-regression models (p=0.074 for trastuzumab use).
Conclusion: Cross-talk between ER and EGFR/HER2 pathways may mitigate trastuzumab effect in HER2+ve/ER+ve breast cancers. Further study is warranted.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P1-12-15.
Collapse
|
39
|
Park YH, Im SA, Cho EY, Ahn JH, Kim S, Keam B, Han W, Park IA, Noh DY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. P2-12-19: Nomogram To Predict Recurrence and To Avoid Unnecessary Adjuvant Chemotherapy Based on Ki67 Index and ER Status in Hormone Receptor (HR)-Positive Breast Cancers with Low Number of Nodal Metastases (≤3) (NCT01273415). Cancer Res 2011. [DOI: 10.1158/0008-5472.sabcs11-p2-12-19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Hormone receptor (HR) positive breast cancers characterized with ER-associated genes are differentiated luminal B from luminal A tumors mainly by proliferation genes. According to NCCN guideline 2011, node positivity has been a main determinant to decide adjuvant chemotherapy with category 1. However, the experts’ panel at the St. Gallen Consensus in 2009 do not provides definite indications to give or withhold chemotherapy in patient group with intermediate criteria including low numbers (1-3, N1) of involved lymph nodes. Thus, in cases of limited number of nodal metastases, the role of biologic factors including Ki67 index needs to be defined. The aims of this study are to evaluate of Ki67 index as a useful surrogate marker to predict recurrence and to avoid unnecessary adjuvant chemotherapy and to develop nomogram based on Ki67 index to determine adjuvant therapeutic options in HR-positive in N0 and N1 breast cancers.
Patients and Methods
We retrospectively analyzed the clinicopathologic characteristics and outcomes of 953 postoperative HR-positive N0 and N1 breast cancer patients between 2004 and 2007 at the Samsung Medical Center. We constructed nomogram based on Cox regression model using independent factors demonstrated in multivariate analysis and validated externally in a cohort of 895 patients treated at Seoul National University Hospital.
Results: In Cox regression multivariate analysis, ER-ve/PgR+ve and Ki67 index were identified as independent factors.
Nomogram base on Cox-regression model showed an AUC of 0.75 (95% CI, 0.72−0.77) in the training set. The validation set showed a good discrimination with an AUC of 0.63 (95% CI, 0.60−0.66). We defined low nomogram score as less than 53, and high nomogram score as 53 or more from the cut-off value of the nomogrma ROC curve. Patients who received anthracycline-containing adjuvant chemotherapy with high nomogram scores showed better RFS with statistical significance than those who did not receive anthracycline-containing adjuvant chemotherapy with high nomogram scores (p<0.0001). In contrast, the patients with low nomogram scores did not show any benefit from anthracycline-containing adjuvant chemotherapy (p=0.804). When the patients with high nomogram scores divided into two groups according to Allred ER scores (0-4 vs 5–8), the patients with high ER Allred scores (5-8) and high nomogram scores did not show any benefit from anthracycline-containing chemotherapy (p=0.283). Main benefit from adjuvant chemotherapy is focused on the patients with low ER Allred scores (0-4) and high nomogram score (p=0.022).
Conclusion: Ki67 index is useful as a valuable surrogate marker to predict recurrence and to avoid unnecessary chemotherapy. Nomogram based on Ki67 index is constructed and validated to determine adjuvant therapeutic options in HR-positive N0 and N1 breast cancers.
Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P2-12-19.
Collapse
Affiliation(s)
- YH Park
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - S-A Im
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - EY Cho
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - JH Ahn
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - S Kim
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - B Keam
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - W Han
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - IA Park
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - D-Y Noh
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - JE Lee
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - SJ Nam
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - JH Yang
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - JS Ahn
- 1Samsung Medical Center; Seoul National University College of Medicine
| | - Y-H Im
- 1Samsung Medical Center; Seoul National University College of Medicine
| |
Collapse
|
40
|
Abstract
The objective of this study was to evaluate the prevalence of asthma, allergic rhinitis, and atopic dermatitis, as well as the risk factors of wheezing among young adults in the Korean military. Young military conscripts in five areas completed a modified International Study of Asthma and Allergies in Childhood (ISAAC) questionnaire. For subjects with current wheeze in one sample area, baseline spirometry and bronchodilator response were measured. For subjects without a significant response to bronchodilator (improvement in FEV1 of more than 200 mL and 12%), methacholine challenge tests (MCT) were also performed. Of 3,359 subjects that completed the questionnaire, 354 (10.5%) had current wheeze, 471 (14.0%) had current allergic rhinitis, and 326 (9.7%) had current eczema. Current wheeze was associated with family history of allergic disease, overweight, current smoking, allergic rhinitis, and atopic dermatitis. Of 36 subjects with current wheeze who underwent PFT with or without MCT in the Anyang area, 24 (66.7%) were confirmed to have current asthma. In conclusion, the prevalence of allergic disease in young adults of Korean military is not low, and the risk factors of wheezing include family history of allergic disease, overweight, current smoking, allergic rhinitis, and atopic dermatitis.
Collapse
Affiliation(s)
- Sang Min Lee
- Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea
| | - Jong Seong Ahn
- Commander, Armed Forces Chunchun Hospital, Chunchun, Korea
| | - Chang Suk Noh
- Department of Pulmonary and Critical Care Medicine, and Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Sei Won Lee
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
| |
Collapse
|
41
|
Park YH, Ok ON, Seo JJ, Cho EY, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Abstract P2-06-01: Ki67 Proliferative Index as an Invaluable Biomarker in Hormone Receptor (HR)-Positive Breast Cancer: Ki67 Labelling Index Can Reflect the Differences between Luminal A and B Subtypes Better Than HER2 Expression. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-06-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Differentiation by multigene signatures with excellent performance of hormone receptor (HR)-positive BC largely related to their proliferation genes. Despite questions about its usefulness, there is increasing evidence that Ki67 is a valuable prognostic marker. Standardization of Ki67 pathological assessment is the main problem to interpret reported trials.
The aims of the study are to evaluate the role Ki67 as prognostic marker to predict relapse in HR-positive BC patients (luminal A and B) in adjuvant setting using prospective patients’ cohort. In addition, cut-off value and significant level of Ki67 were investigated comparing with other biomarkers including HER2 in luminal BCs.
Method: We retrospectively analyzed the clinicopathologic characteristics of 1,070 postoperative breast cancer patients including Ki67 and clinical outcomes in terms of relapse free survival (RFS) between 2004 and 2007 at the Samsung Medical Center. Ki67 labelling index was measured in quantitative and semiquantitative method, independently. The percentage of positive nuclei stained for Ki67 was calculated each section based on the approximately 1,000 carcinoma cell nuclei. In addition, Ki67 was graded on a scale from 0 to 4, where 0 = staining of 0-4% of tumor cells, 1 = staining of 5-25% of tumor cells, 2 = 26-50% of tumor cells, 3 = staining of 51-75% of tumor cells, and 4 = staining of more than 76% of tumor cells. ROC curve was drawn to evaluate the usefulness of Ki67 index to get AUC then, find out the proper cut-off value of Ki67 to predict relapse. Multivariate analyses with Cox-regression model were performed. Results: Among 1,564 patients who received curative surgery for invasive breast cancer from January 2004 to June 2007, 1,070 patients with HR-positive were included in this analysis excluding 494 with HER2-enriched or triple negative breast cancer patients. Median follow-up duration was 56.9 months (range 36-77 months). Median age was 46 years (range 22-83 years). Ki67 threshold >19.5%, corresponding to a sensitivity 78.3%, a specificity 51.6% was chosen as cut-off value for relapse in adjuvant patients’ cohort. The AUC was 0.689 (P<0.0001 by Mann-Whitney U test). Overall relapse rate was 5.6%. In univariate analysis by log-rank test for relapse, ER negativity (p=0.010), HER2 positivity (p=0.017), histologic (p=0.001), and nuclear grade (p=0.012), lymphovascular invasion (P<0.0001), TNM stage (0.001), and Ki67 (P<0.0001) were identified risk factors to predict relapse. However, ER negativity, Ki67, and stage were identified as independent risk factors for relapse (Hazard Ratio (HR) 2.7, p=0.031 for ER negativity, HR 3.4, p <0.0001 for Ki67, HR 1.6, p=0.017 for stage) in Cox-regression multivariate analysis. Conclusion: Ki67 could strongly predict clinical outcomes for patients with luminal. 19.5% may be useful cut-off value of Ki67 labelling index. Ki67 may be a better biomarker to predict clinical outcomes than HER2 expression in luminal BCs. ER-/PR+ subset probably has different biology with other luminal BCs. Prospective clinical trials to choose therapeutic option using Ki67 are warranted.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-06-01.
Collapse
|
42
|
Jung HH, Park YH, Ahn JS, Im YH. Abstract P5-05-13: HER2-Induced MMP-1 Expression Is Mediated by HER1 Though AR, EGF, and TGF Independent of HER3 through HRG in Breast Cancer Cells. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p5-05-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
introduction. However, one of plausible explanation for resistance to trastuzumab is associated with HER dimerization. Furthermore, HER3 seems to be the preferred dimerization partner when signaling occurs through the PI3K pathway and, as such, is emerging as a key target for inhibition of HER signaling. Recently, we reported that HER2 could induce enhanced MMP-1 expression. In addition, this up-regulation of MMP1 expression was shown to be mediated MAPK pathway synergized with ER. Heregulin (HRG) acts as a preferential ligand for HER3 and/or HER4 receptors. Upon binding, HRG activates the EGFR/HER2 receptors via dimerization with HER3 and/or HER4. In the other words, HRG-β was reported to promote MMP-7 expression via HER2-mediated AP-1 activation in MCF-7 cells. In addition, MMP-9 is associated with HRG-≥1/HER2 aggressive phenotype of breast cancer.
Based on these backgrounds, we conducted this study to test the role of HER3 in breast cancer cells in relation to the expression of HER2 and MMP-1.
Our result showed that MMP-1 and MMP-13 expressions were up-regulated via EGF and amphiregulin (AR) independent of HRG in HER2 transfected MCF-7 and SK-BR-3 breast cancer cells through Western immunoblotting and quantitative RT-PCR. Enhanced MMP-1 and MMP-13 expressions were markedly decreased by treating HER2 targeting agents in AR, EGF, and TGF-β stimulating cell lines, while these findings were not observed in HRG1-β and HRG1-β stimulating cell lines in quantitative RT-PCR. In addition, these findings were reversed by treating siEGFR and siHER2, not by siHER3. Consequently, we could confirm the downstream pathways were mediated by MMP-1 AP-1 not by HRG1-β, nor HRG1-β with EMSA.
This study showed that HER2-induced MMP-1 expression was mediated by HER1 though AR, EGF, and TGF independent of HER3 through HRG in breast cancer cells. This result implies that the dimerization responsible for MMP-1 up-regulation by HER2 is HER1/HER2, not HER2/HER3. Further implications of MMP-1 in HER2 overexpressing breast cancer through HER1 are going to following.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-05-13.
Collapse
Affiliation(s)
- HH Jung
- Samsung Medical Center Trastuzumab, HER2-directed monoclonal antibody, has shown markedly improved clinical outcomes in HER2-overexpressing breast cancer after
| | - YH Park
- Samsung Medical Center Trastuzumab, HER2-directed monoclonal antibody, has shown markedly improved clinical outcomes in HER2-overexpressing breast cancer after
| | - JS Ahn
- Samsung Medical Center Trastuzumab, HER2-directed monoclonal antibody, has shown markedly improved clinical outcomes in HER2-overexpressing breast cancer after
| | - Y-H. Im
- Samsung Medical Center Trastuzumab, HER2-directed monoclonal antibody, has shown markedly improved clinical outcomes in HER2-overexpressing breast cancer after
| |
Collapse
|
43
|
Lee S, Nam DH, Lee JI, Park W, Choi DH, Huh SJ, Park YH, Ahn JS, Im YH. Abstract P6-13-05: Differences of Clinical Manifestations and Therapeutic Outcomes in Leptomeningeal Metastases (LM) According to Breast Cancer Subtypes. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-13-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Backgrounds: Breast cancer is the solid tumor most commonly associated with leptomeningeal metastases (LM). Therapeutic modalities include intrathecal and systemic chemotherapy, radiotherapy and other palliative modality including placement of a ventricular reservoir. The aim of this study is to characterize clinical feature and outcomes of LM according to breast cancer subtypes in conjunction with whole CNS metastases.
Methods: A retrospective study was performed on breast cancer patients with LM who received palliative management at Samsung Medical Center between 1994 and 2008. Among 281 metastatic breast cancer patients, 71 breast cancer patients with LM were identified. They were divided into three biological subgroups. The propensity of biological subtypes for LM, clinical manifestation including recursive partitioning analysis of Radiation Therapy Oncology Group (RPA RTOG) prognostic class, and therapeutic outcomes were assessed.
Results: The median age was 48 (range 26-70) years. The rates of the patients with triple negative breast cancer (TNBC), human epidermal growth factor receptors 2 (HER2)-positive and hormone receptor (HR)- positive subtype breast cancer were 26 (44%), 15 (25%) and 18 (31%), respectively. Sixty-four patients (90%) had metastatic disease at sites other than LM. TNBC were more common in RPA RTOG prognostic class III than those in HER2 and HR-positive subtypes (61% vs 39% vs 0%, P<0.0001). CNS including LM was the first site of distant metastasis in 65% of the TNBC patients. Treatment includes intrathecal chemotherapy (IT), whole brain radiotherapy (WBRT), and systemic chemotherapy. The median survival duration from the diagnosis of LM to death (OS-LM) was 4.5 months (range 0.2-26.4 months). Main causes of death were deterioration of neurologic sequelae associated with LM (55%), systemic disease progression (27%), and et cetera (18%). Death rates related with LM at each subtype were 64% for TNBC, 36% for HER2-positive, and 0% for HR-positive patients (p=0.060). In the univariate analysis, RPA RTOG classification (p=0.003), systemic disease control at LM (p=0.041), cytologic negative conversion to IT (p=0.001), systemic chemotherapy after LM diagnosis (p=0.002), and combined modality for LM treatment (p=0.005) were singled out as having prognostic value for OS-LM. Cox-regression multivariate analysis showed that RPA class (HR (Hazard Ratio) 1.8, p=0.022), cytologic negative conversion to IT (HR 0.4, p=0.043), and systemic chemotherapy (HR 0.24, p=0.004) are identified as independent prognostic factors.
Conclusion: TNBC and HER2-positive breast cancer appeared to have special predilection for LM as well as brain parenchymal metastases. High RPA class of TNBC may reflect more aggressive tumor biology in this sanctuary area. OS-LM depended on RPA class, cytologic negative conversion, and the use of systemic chemotherapy. The role of systemic chemotherapy and active local treatment modalities according to subtypes should be defined to improve dismal prognosis.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-13-05.
Collapse
|
44
|
Moon JH, Kim SN, Kang BW, Chae YS, Kim JG, Ahn JS, Kim YK, Yang DH, Lee JJ, Kim HJ, Choi YJ, Shin HJ, Chung JS, Cho GJ, Sohn SK. Early onset of acute GVHD indicates worse outcome in terms of severity of chronic GVHD compared with late onset. Bone Marrow Transplant 2010; 45:1540-5. [PMID: 20190848 DOI: 10.1038/bmt.2010.12] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Acute GVHD (aGVHD) is an important risk factor for predicting the incidence or severity of chronic GVHD (cGVHD). Transplant outcome can be influenced by the onset time of aGVHD in patients who have received allogeneic PBSC transplants (PBSCTs). The medical records of 134 patients who survived more than 3 months after myeloablative allogeneic PBSCT were retrospectively reviewed. In all, 38 patients (28.4%) developed grade II-IV aGVHD before day +28 (early aGVHD) and 25 patients (18.7%) after day +28 (late aGVHD). The 5-year cumulative incidence of cGVHD was 78.9% in the early-aGVHD group and 56.6% in the late-aGVHD group (P=0.034). The 5-year OS was 51.0% for the early-aGVHD and 80.8% for the late-aGVHD group (P=0.406). Infection was the primary cause of death for the early-aGVHD group (51.4 vs 16.7%, P=0.017), whereas relapse of the primary disease was higher among the patients with late aGVHD, although this was statistically insignificant (58.3 vs 25.7%, P=0.309). In a multivariate analysis, early aGVHD was identified as a risk factor for developing cGVHD (hazard ratio (HR) 2.278, P=0.004). The development of aGVHD early after allogeneic PBSCT increased the risk of cGVHD and infection-related death rate when compared with the late onset of aGVHD.
Collapse
Affiliation(s)
- J H Moon
- Department of Hematology/Oncology, Kyungpook National University Hospital, Daegu, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Abstract
BACKGROUND AND PURPOSE Dissecting vertebrobasilar aneurysms are challenging to treat, and standard treatment modalities remain controversial. We retrospectively evaluated our experience using endovascular techniques to treat these aneurysms. MATERIALS AND METHODS From February 1997 to December 2007, 42 patients with intradural vertebrobasilar dissecting aneurysms underwent endovascular treatment. Twenty-nine patients had ruptured aneurysms, and 13 patients had unruptured dissecting aneurysms. The endovascular modalities for vertebrobasilar dissecting aneurysms were the following: 1) trapping (n = 30), 2) proximal occlusion (n = 3), 3) stent with coil (n = 6), and 4) stent alone (n = 3). RESULTS Seventeen of the 29 patients with ruptured vertebrobasilar dissecting aneurysms had successful outcomes without procedural complications following endovascular treatment. Procedure-related complications were the following: 1) rebleeding (n = 3), 2) posterior inferior cerebellar artery (PICA) territory infarction (n = 6), 3) brain stem infarction (n = 2), and 4) thromboembolism-related multiple infarctions (n = 1). Clinical outcomes were favorable in 32 patients (76.1%). There were 3 (7.1%) procedure-related mortalities due to rebleeding, and 1 (2.4%) non-procedure-related mortality due to pneumonia sepsis. All 13 patients with unruptured vertebrobasilar dissecting aneurysms had favorable clinical and radiologic outcomes without procedure-related complications. CONCLUSIONS Endovascular procedures for treatment of unruptured symptomatic dissecting aneurysms resulted in favorable outcomes. Ruptured vertebrobasilar dissecting aneurysms are associated with a high risk of periprocedural complications. Risks can be managed by using appropriate endovascular techniques according to aneurysm location, configuration, and relationship with the PICA.
Collapse
Affiliation(s)
- S-C Jin
- Department of Neurological Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | | | | | | | | |
Collapse
|
46
|
Ahn JS, Kihm HW, Kihm JE, Kim DS, Lee KG. 3-dimensional local field polarization vector mapping of a focused radially polarized beam using gold nanoparticle functionalized tips. Opt Express 2009; 17:2280-2286. [PMID: 19219131 DOI: 10.1364/oe.17.002280] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
We have measured local electric field polarization vectors in 3-dimensional space on the nanoscale. A radial polarized light is generated by using a radial polarization converter and focused by an objective lens. Gold nanoparticle functionalized tips are used to scatter the focused field into the far-field region. Two different methods, rotational analyzer ellipsometry and Stokes parameters, are used in determining the polarization state of the scattered light. Two methods give consistent results with each other. Three dimensional local polarization vectors could be reconstructed by applying back transformation of the fully characterized polarizability tensor of the tip.
Collapse
Affiliation(s)
- J S Ahn
- Department of Physics and Astronomy, Seoul National University, Seoul 151-747, Korea
| | | | | | | | | |
Collapse
|
47
|
Kim A, Kwon OS, Kim SO, He L, Bae EY, Lee MS, Jeong SJ, Shim JH, Yoon DY, Kim CH, Moon A, Kim KE, Ahn JS, Kim BY. Caspase-3 activation as a key factor for HBx-transformed cell death. Cell Prolif 2008; 41:755-74. [PMID: 18700866 DOI: 10.1111/j.1365-2184.2008.00550.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
OBJECTIVES Nuclear factor-kappa B (NF-kappaB) activation has been associated with the tumorigenic growth of hepatitis B virus X protein (HBx)-transformed cells. This study was aimed to find a key target for treatment of HBx-mediated cancers. MATERIALS AND METHODS NF-kappaB activation, endoplasmic reticulum-stress (ER-stress), caspase-3 activation, and cell proliferation were evaluated after Chang/HBx cells permanently expressing HBx viral protein were treated with inhibitors of NF-kappaB, proteasome and DNA topoisomerase. RESULTS Inhibition of NF-kappaB transcriptional activity by transient transfection with mutant plasmids encoding Akt1 and glycogen synthase kinase-3beta (GSK-3beta), or by treatment with chemical inhibitors, wortmannin and LY294002, showed little effect on the survival of Chang/HBx cells. Furthermore, IkappaBalpha (S32/36A) mutant plasmid or other NF-kappaB inhibitors, 1-pyrrolidinecarbonidithioic acid and sulphasalazine, were also shown to have little effect on the cell proliferation. By contrast, proteasome inhibitor-1 (Pro1) and MG132 enhanced the HBx-induced ER-stress response and the subsequent activation of caspase-12, -9 and -3 and reduced cell proliferation. Camptothecin (CPT), however, triggered activation of caspase-3 without induction of caspase-12, and reduced cell proliferation. In addition, CPT-induced cell death was reversed by pre-treatment with z-DEVD, a caspase-3-specific inhibitor. CONCLUSIONS Detailed exploitation of the regulators of caspase-3 activation could open the gate for finding an efficient target for development of anticancer therapeutics against HBx-transformed hepatocellular carcinoma.
Collapse
Affiliation(s)
- A Kim
- Functional Metabolomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Yuseong, South Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Lee KG, Ahn KJ, Kihm HW, Ahn JS, Kim TK, Hong S, Kim ZH, Kim DS. Surface plasmon polariton detection discriminating the polarization reversal image dipole effects. Opt Express 2008; 16:10641-10649. [PMID: 18607478 DOI: 10.1364/oe.16.010641] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Image dipole effects are highly dependent on the polarization direction, constructive (destructive) interference between real and image dipoles for the vertically (horizontally) aligned one in the vicinity of metal surfaces, respectively. This polarization-reversal of the image dipole effects is quantitatively investigated by using a gold nanoparticle functionalized tip as a local dipolar scatterer and a propagating surface plasmon polariton as an excitation source of dipoles. The polarization-resolved detection technique is applied to separate the radiations of the vertical and the horizontal dipoles from each other. In our study, the image dipole effects on the far-field detected signals are fully explained by the Fabry-Perot like interference between the radiations from the real and the image dipoles, and by considering the finite size effects of the gold nanoparticle.
Collapse
Affiliation(s)
- K G Lee
- Department of Physics and Astronomy, Seoul National University, Seoul 151-747, Korea
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Loudon JC, Kourkoutis LF, Ahn JS, Zhang CL, Cheong SW, Muller DA. Valence changes and structural distortions in "charge ordered" manganites quantified by atomic-scale scanning transmission electron microscopy. Phys Rev Lett 2007; 99:237205. [PMID: 18233407 DOI: 10.1103/physrevlett.99.237205] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/16/2007] [Indexed: 05/25/2023]
Abstract
We investigate the microscopic nature of the "charge ordering" modulation in mixed-valent manganites in real space using scanning transmission electron microscopy. The modulation in Bi0.5Sr0.4Ca0.1MnO3 has a uniform periodicity appearing as stripes in high angle annular dark field images. Geometric phase analysis shows the modulation to be a displacement wave with transverse amplitude (0.008+/-0.001)a and longitudinal amplitude (0.003+/-0.001)a. Series of energy loss spectra taken across the stripes show no periodic changes and place an upper bound of +/-0.04 on any valence changes of the Mn ions.
Collapse
Affiliation(s)
- J C Loudon
- School of Applied and Engineering Physics, Cornell University, Ithaca, New York 14853, USA
| | | | | | | | | | | |
Collapse
|
50
|
Lee KG, Kihm HW, Ahn KJ, Ahn JS, Suh YD, Lienau C, Kim DS. Vector field mapping of local polarization using gold nanoparticle functionalized tips: independence of the tip shape. Opt Express 2007; 15:14993-15001. [PMID: 19550780 DOI: 10.1364/oe.15.014993] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We have measured local electric field vectors of local polarizaton on the nanoscale using gold nanoparticle functionalized tips as local field scatterers. In our experiments, the local field induces a dipole-moment in the gold nanoparticle functionalized tip, which then radiates into the far-field, transferring the full information about the local electric field from the near into the far field. The polarization characteristics of the scattered fields are analyzed using a conventional ellipsometry method. The tip dependent scattering function- the polarizability tensor- is fully determined by far field scattering measurements. Once the polarizability tensor for each tip is correctly accounted for in the data analysis, our results show that the finally determined local field polarization vectors are essentially independent of the tip shape.
Collapse
|